PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
C07K 14/415, C12N 15/82, A01H 5/00
A1
(11) International Publication Number: WO 00/01722
(43) International Publication Date: 13 January 2000 (13.01.00)

(21) International Application Number: PCT/US99/15255

(22) International Filing Date: 7 July 1999 (07.07.99)

(30) Priority Data: 60/091,875 7 July 1998 (07.07.98) US

(71) Applicant (for all designated States except US): PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 800 Capital Square, 400 Locust Street, Des Moines, IA 50319 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): BRIGGS, Steven, P.

[US/US]; 2454 Mango Way, Del Mar, CA 92014 (US). SIMMONS, Carl, R. [US/US]; 4228 Holland Drive, Des Moines, IA 50310 (US).

(74) Agents: SPRUILL, W., Murray et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US). (81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: MANIPULATION OF MLO GENES TO ENHANCE DISEASE RESISTANCE IN PLANTS

Maize MLO Resistance Gene Homologues



(57) Abstract

Compositions and methods for enhancing disease resistance in plants are provided. The method involves modulating the activity of *Mlo* sequences in the plant. Particular *Mlo* sequences are provided that can be manipulated to enhance pathogen resistance in modified plants. Transformed plants, plant cells, tissues, and seed are also provided having enhanced disease resistance.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
|----|--------------------------|-----|---------------------|----|-----------------------|------|--------------------------|
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | Prance | LU | Luxembourg | SN | Senegal |
| ΑU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | 1E | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US · | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | zw | Zimbabwe |
| Cl | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | 311104040 |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | rc | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | l,I | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | , |

MANIPULATION OF *MLO* GENES TO ENHANCE DISEASE RESISTANCE IN PLANTS

FIELD OF THE INVENTION

5

10

15

20

25.

30

The invention relates to the genetic manipulation of plants, particularly to transforming plants with genes that enhance disease resistance.

BACKGROUND OF THE INVENTION

Disease in plants is caused by biotic and abiotic causes. Biotic causes include fungi, viruses, bacteria, and nematodes. Of these, fungi are the most frequent causative agent of disease on plants. Abiotic causes of disease in plants include extremes of temperature, water, oxygen, soil pH, plus nutrient-element deficiencies and imbalances, excess heavy metals, and air pollution.

A host of cellular processes enables plants to defend themselves from disease caused by pathogenic agents. These processes apparently form an integrated set of resistance mechanisms that is activated by initial infection and then limits further spread of the invading pathogenic microorganism. This limitation of the pathogen intruder is frequently accomplished by localized containment of the intruder following a coordinated complex defense response.

Subsequent to recognition of a potentially pathogenic microbe, plants can activate an array of biochemical responses. Generally, the plant responds by inducing several local responses in the cells immediately surrounding the infection site. The most common resistance response observed in both nonhost and race-specific interactions is termed the "hypersensitive response" (HR). In the hypersensitive response, cells contacted by the pathogen, and often neighboring cells, rapidly collapse and dry in a necrotic fleck. Other responses include the deposition of callose, the physical thickening of cell walls by lignification, and the synthesis of various antibiotic small molecules and proteins. Genetic factors in both the host and the pathogen determine the specificity of these local responses, which can be very effective in limiting the spread of infection.

The hypersensitive response in many plant-pathogen interactions is specified by and dependent on the presence of two complementary genes, one from the host and one from the pathogen. These complementary genes are the resistance (R) gene in the plant and a corresponding avirulence (avr) gene in the pathogen. The interaction of the genes is associated with the rapid, localized cell death of the hypersensitive response. R genes that respond to specific bacterial, fungal, or viral pathogens, have been isolated from a variety of plant species and several appear to encode cytoplasmic proteins.

5

10

15

20

25

30

The resistance gene in the plant and the avirulence gene in the pathogen often conform to a gene-for-gene relationship. That is, resistance to a pathogen is only observed when the pathogen carries a specific avirulence gene and the plant carries a corresponding or complementing resistance gene. Because avr-R gene-for-gene relationships are observed in many plant-pathogen systems and are accompanied by a characteristic set of defense responses, a common molecular mechanism underlying avr-R gene mediated resistance has been postulated. A simple model which has been proposed is that pathogen avr genes directly or indirectly generate a specific molecular signal (ligand) that is recognized by cognate receptors encoded by plant R genes.

Both plant resistance genes and corresponding pathogen avirulence genes have been cloned. The plant kingdom contains thousands of R genes with specific specificities for viral, bacterial, fungal, or nematode pathogens. Although there are differences in the defense responses induced during different plant-pathogen interactions, some common themes are apparent among R genemediated defenses. The function of a given R gene is dependent on the genotype of the pathogen. Plant pathogens produce a diversity of potential signals, and in a fashion analogous to the production of antigens by mammalian pathogens, some of these signals are detectable by some plants.

The avirulence gene causes the pathogen to produce a signal that triggers a strong defense response in a plant with the appropriate R gene. However, expressing an avirulence gene does not stop the pathogen from being virulent on hosts that lack the corresponding R gene. A single plant can have many R genes, and a pathogen can have many avr genes.

Monogenic resistance mediated by recessive (*mlo*) alleles of the *Mlo* locus is different. It differs from race-specific incompatibility to single pathogen strains in that it is believed to confer a broad spectrum resistance to almost all known isolates of the fungal pathogen, and the resistance is apparently durable in the field despite extensive cultivation. Further, *mlo* resistance alleles have been obtained by mutagen treatment of susceptible wild-type *Mlo* varieties. These *mlo* plants exhibit a spontaneous leaf cell death phenotype under pathogen-free or even axenic conditions.

As noted, among the causative agents of infectious disease of crop plants, the phytopathogenic fungi play the dominant role. Phytopathogenic fungi cause devastating epidemics, as well as causing significant annual crop yield losses. All of the approximately 300,000 species of flowering plants are attacked by pathogenic fungi. However, a single plant species can be host to only a few fungal species, and similarly, most fungi usually have a limited host range.

Plant disease outbreaks have resulted in catastrophic crop failures that have triggered famines and caused major social change. Generally, the best strategy for plant disease control is to use resistant cultivars selected or developed by plant breeders for this purpose. However, the potential for serious crop disease epidemics persists today, as evidenced by outbreaks of the Victoria blight of oats and southern corn leaf blight.

Accordingly, molecular methods are needed to supplement traditional breeding methods to protect plants from pathogen attack. Particularly, methods are needed for broad spectrum resistance to pathogens.

5

10

15

20

5

10

15

20

25

herein.

SUMMARY OF THE INVENTION

Compositions and methods for creating or enhancing resistance to plant pests are provided. The method provides control of pathogens by modulating the expression of *Mlo* genes. Novel *Mlo* sequences are provided from maize. Such sequences can be utilized to modulate the expression of *Mlo* genes in plants, particularly maize, to enhance resistance to pathogens. Generally, such modulation will result in decreased or increased expression of native *Mlo* genes, preferably decreased expression. Such decreased expression can be effected by mutagenesis or expression of modified or antisense *Mlo* sequences described

It is recognized that a variety of promoters will be useful in the invention the choice of which will depend in part upon the desired level of expression of the modified sequences in the plant or alternatively, in the plant organ. It is recognized that the levels of expression can be controlled to induce broad spectrum resistance resulting in levels of immunity in the plant or to induce cell death.

The methods of the invention find use in controlling plant pests, including fungal pathogens, viruses, nematodes, insects, and the like.

Transformed plants and seeds, as well as methods for making such plants and seeds are additionally provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a sequence alignment for the maize *Mlo* homologues with the barley *Mlo* sequence. The barley sequence is designated as Hv*Mlo*1.

Figure 2 groups the *Mlo* sequences based on relatedness as well as the plant tissue from which it was isolated.

Figure 3 schematically illustrates a plasmid vector comprising the ZmMo1 antisense construct operably linked to the ubiquition promoter.

DETAILED DESCRIPTION OF THE INVENTION

Compositions of the invention include eight mutation-induced recessive alleles of maize set forth in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13 and 15. The maize sequences exhibit homology to the *Mlo* barley sequence (SEQ ID NO:

- 17). See, Büschges et al. (1997) 88:695-705 and Tables 1 and 2. The isolated maize Mlo genes are involved in enhancing resistance to plant pests. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, or the nucleotide sequences encoding
- the DNA sequences deposited in a bacterial host with the American Type
 Culture Collection and assigned the Accession Nos. 98725, 98726, 98727,
 98728, 98729 (SEQ ID NOS: 3, 5, 9, 11, 13 respectively). Further provided are
 polypeptides having an amino acid sequence encoded by a nucleic acid
 molecule described herein, for example those set forth in SEQ ID NOS: 1, 5, 3,
- 7, 9, 11, 13, and 15, those deposited with the American Type Culture Collection and assigned Accession Nos. 98725, 98726, 98727, 98728, 98729 (SEQ ID NOS: 3, 5, 9, 11, 13 respectively), and fragments and variants thereof.

20

25

30

Plasmids containing the nucleotide sequences of the invention were deposited with American Type Culture Collection, Manassas, Virginia, and assigned Accession Nos. 98725, 98726, 98727, 98728, 98729 (SEQ ID NOS: 3, 5, 9, 11, 13 respectively). These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112.

The invention encompasses isolated or substantially purified nucleic acid or protein compositions. An "isolated" or "purified" nucleic acid molecule or protein, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic

5

10

15

20

25

30

DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, (by dry weight) of contaminating protein. When the protein of the invention or biologically active portion thereof is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.

Fragments and variants of the disclosed nucleotide sequences and proteins encoded thereby are also encompassed by the present invention. By "fragment" is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence their altered expression enhances resistance to pathogens. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not encode protein fragments retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the proteins of the invention.

A fragment of a *Mlo* nucleotide sequence that encodes a biologically active portion of a Mlo protein of the invention will encode at least 15, 20, 25, 30, 40, 50, 75, 100, 200, 250, 300, 350, 400, 450, 500, or 550 contiguous amino acids, or up to the total number of amino acids present in a full-length MLO protein of the invention. (For example, 509, 499, and 492, amino acids for SEQ ID NOS: 6, 12, and 14 respectively.) Fragments of a *Mlo* nucleotide sequence that are useful as hybridization probes for PCR primers generally need not encode a biologically active portion of a MLO protein.

Thus, a fragment of a *Mlo* nucleotide sequence may encode a biologically active portion of a MLO protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below.

A biologically active portion of a MLO protein can be prepared by isolating a portion of one of the *Mlo* nucleotide sequences of the invention, expressing the encoded portion of the MLO protein (e.g., by recombinant expression *in vitro*), and assessing the activity of the encoded portion of the MLO protein. Nucleic acid molecules that are fragments of a *Mlo* nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, and 2,000 nucleotides, or up to the number of nucleotides present in a full-length *Mlo* nucleotide sequence disclosed herein.

5

10

15

20

25

30

By "variants" is intended substantially similar sequences. For nucleotide sequences, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the MLO polypeptides of the invention. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis but which still encode a MLO protein of the invention. Generally, nucleotide sequence variants of the invention will have at least 40%, 50%, 60%, 70%, generally, 80%, preferably 85%, 90%, up to 95%, 98% sequence identity to its respective native nucleotide sequence.

By "variant" protein is intended a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Such variants may result from, for example, genetic polymorphism or from human manipulation.

The proteins of the invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of the Mlo proteins can be prepared by mutations in the DNA.

Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; US Patent No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff et al. (1978) Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred.

5

10

15

20

25

30

Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as mutant forms. Likewise, the proteins of the invention encompass both naturally occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired ability to enhance resistance to pathogens when their expression is altered. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444.

The deletions, insertions, and substitutions of the protein sequences encompassed herein are not expected to produce radical changes in the characteristics of the protein. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by an enhanced resistance to pathogens when the expression of the protein sequences is altered.

Variant nucleotide sequences and proteins also encompass sequences and proteins derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different *Mlo* coding sequences can be manipulated to create a new *Mlo* coding sequence possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising

5

10

15

20

25

30

sequence regions that have substantial sequence identity and can be homologously recombined *in vitro* or *in vivo*. For example, using this approach, sequence motifs encoding a domain of interest may be shuffled between the *Mlo* gene of the invention and other known genes involved in pathogen resistance to obtain a new gene coding for a protein with an improved property of interest, such as an increased K_m in the case of an enzyme. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer (1994) *Proc. Natl. Acad. Sci. USA 91*:10747-10751; Stemmer (1994) *Nature 370*:389-391; Crameri *et al.* (1997) *Nature Biotech. 15*:436-438; Moore *et al.* (1997) *J. Mol. Biol. 272*:336-347; Zhang *et al.* (1997) *Proc. Natl. Acad. Sci. USA 94*:4504-4509; Crameri *et al.* (1998) *Nature 391*:288-291; and U.S. Patent Nos. 5,605,793 and 5,837,458.

The maize *Mlo* homologues are associated with disease related loci as shown in Table 3. Mapping information of the sequences are given in Table 5. The maize homologue proteins are predicted to be membrane-anchored by at least six, and possibly seven membrane-spanning helices. The maize sequences find use in negative control function of the MLO protein in leaf cell death and in the onset of pathogen defense. Generally, the methods of the invention take advantage of the absence of MLO to prime responsiveness of the plant to disease.

The nucleotide sequences of the invention can be used to isolate corresponding sequences from other organisms, particularly other plants, more particularly other monocots. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire *Mlo* sequences set forth herein or to fragments thereof are encompassed by the present invention.

In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any plant of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). See also Innis et al.,

eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers, and the like.

10

15

20

25

30.

In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as ³²P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the *Mlo* sequences of the invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

For example, the entire sequence of the *Mlo* nucleotide sequences disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding *Mlo* sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among *Mlo* sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding *Mlo* sequences from a chosen plant by PCR. This technique may be used to isolate additional coding sequences from a desired plant or as a diagnostic assay to determine the presence of coding sequences in a plant. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook *et al.*

5

10

15

20

25

30

(1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

Hybridization of such sequences may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization conditions" is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C.

Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl (1984) *Anal. Biochem. 138*:267-284: $T_m = 81.5^{\circ}\text{C} + 16.6 \text{ (log M)} + 0.41 \text{ (%GC)} - 0.61 \text{ (% form)} - 500/L; where M is the$

5

10

15

20

25

30

molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1°C for each 1% of mismatching; thus, T_m, hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with >90% identity are sought, the T_m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C lower than the thermal melting point (T_m) . Using the equation, hybridization and wash compositions, and desired T_m, those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45°C (aqueous solution) or 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry , and Molecular Biology—Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, New York); and Ausubel et al., eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley-Interscience, New York). See Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

In general, sequences that encode for a Mlo protein and hybridize to the *Mlo* sequences disclosed herein will be at least 40% to 50% homologous, about 60% to 70% homologous, and even about 80%, 85%, 90%, 95% to 98% homologous or more with the disclosed sequences. That is, the sequence

5

10

15

20

25

30

1

similarity of sequences may range, sharing at least about 40% to 50%, about 60% to 70%, and even about 80%, 85%, 90%, 95% to 98% sequence similarity.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity".

- (a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
- (b) As used herein, "comparison window" makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.

Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; by the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443; by the search for similarity method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:2444; by computerized implementations of these algorithms, including, but not limited to: CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California; GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA; the CLUSTAL program is well described by Higgins et al. (1988) Gene 73:237-244 (1988); Higgins et al. (1989) CABIOS 5:151-153; Corpet et al. (1988) Nucleic Acids Res. 16:10881-90; Huang et al. (1992) Computer Applications in the

5

10

15

20

25

30

Biosciences 8:155-65, and Person et al. (1994) Meth. Mol. Biol. 24:307-331; preferred computer alignment methods also include the BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J. Mol. Biol. 215:403-410). Alignment is also often performed by inspection and manual alignment.

(c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity.

Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California).

value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total

5

10

15

20

25

30

number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

(e)(i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90%, and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions.

Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1°C to about 20°C, depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

(e)(ii) The term "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman *et al.* (1970) *J. Mol.*

5

10

15

20

25

30

Biol. 48:443. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are "substantially similar" share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes.

The invention is drawn to methods for creating or enhancing resistance in a plant to plant pests by modulating the activity of *Mlo* genes in the plant. While the invention is not bound by any particular mechanism of action, it is believed that the methods of the invention will result in broad-based resistance in the modified plant. Accordingly, the methods are also useful in protecting plants against fungal pathogens, viruses, nematodes, insects and the like.

By "modulating activity" is intended that the expression of the *Mlo* gene is altered in some manner. Such modulation (increase or decrease) of expression results in enhanced resistance to pathogens. Generally, the methods of the invention will result in a decrease in the native protein or in protein activity. Thus, plants and plant cells are obtained having altered levels of MLO protein, preferably a decrease in protein levels. Such plants, plant cells and plant tissues are "modified" in that MLO protein levels are altered. As noted below, various methods are available for creating modified plants, plant cells and plant tissues including transformation and transfection leading to altered *Mlo* expression in the modified plant, plant cell or tissue.

The invention is drawn to compositions and methods for inducing resistance in a plant to plant pests. Accordingly, the compositions and methods are also useful in protecting plants against fungal pathogens, viruses, nematodes, insects and the like.

By "disease resistance" is intended that the plants avoid the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened. The methods of the invention can be utilized to protect

plants from disease, particularly those diseases that are caused by plant pathogens.

Pathogens of the invention include, but are not limited to, viruses or viroids, bacteria, insects, nematodes, fungi, and the like. Viruses include any 5 plant virus, for example, tobacco or cucumber mosaic virus, ringspot virus, necrosis virus, maize dwarf mosaic virus, etc. Specific fungal and viral pathogens for the major crops include: Soybeans: Phytophthora megasperma fsp. glycinea, Macrophomina phaseolina, Rhizoctonia solani, Sclerotinia sclerotiorum, Fusarium oxysporum, Diaporthe phaseolorum var. sojae 10 (Phomopsis sojae), Diaporthe phaseolorum var. caulivora, Sclerotium rolfsii, Cercospora kikuchii, Cercospora sojina, Peronospora manshurica, Colletotrichum dematium (Colletotichum truncatum), Corynespora cassiicola, Septoria glycines, Phyllosticta sojicola, Alternaria alternata, Pseudomonas syringae p.v. glycinea, Xanthomonas campestris p.v. phaseoli, Microsphaera 15 diffusa, Fusarium semitectum, Phialophora gregata, Soybean mosaic virus, Glomerella glycines, Tobacco Ring spot virus, Tobacco Streak virus, Phakopsora pachyrhizi, Pythium aphanidermatum, Pythium ultimum, Pythium debaryanum, Tomato spotted wilt virus, Heterodera glycines Fusarium solani; Canola: Albugo candida, Alternaria brassicae, Leptosphaeria maculans, 20 Rhizoctonia solani, Sclerotinia sclerotiorum, Mycosphaerella brassiccola, Pythium ultimum, Peronospora parasitica, Fusarium roseum, Alternaria alternata; Alfalfa: Clavibater michiganese subsp. insidiosum, Pythium ultimum, Pythium irregulare, Pythium splendens, Pythium debaryanum, Pythium aphanidermatum, Phytophthora megasperma, Peronospora trifoliorum, Phoma medicaginis var. medicaginis, Cercospora medicaginis, 25 Pseudopeziza medicaginis, Leptotrochila medicaginis, Fusarium, Xanthomonas campestris p.v. alfalfae, Aphanomyces euteiches, Stemphylium herbarum, Stemphylium alfalfae; Wheat: Pseudomonas syringae p.v. atrofaciens, Urocystis agropyri, Xanthomonas campestris p.v. translucens, Pseudomonas 30 syringae p.v. syringae, Alternaria alternata, Cladosporium herbarum, Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Ustilago tritici, Ascochyta tritici, Cephalosporium gramineum, Collotetrichum graminicola, Erysiphe graminis f.sp. tritici, Puccinia graminis f.sp. tritici,

Puccinia recondita f.sp. tritici, Puccinia striiformis, Pyrenophora triticirepentis, Septoria nodorum, Septoria tritici, Septoria avenae, Pseudocercosporella herpotrichoides, Rhizoctonia solani, Rhizoctonia cerealis, Gaeumannomyces graminis var. tritici, Pythium aphanidermatum, Pythium 5 arrhenomanes, Pythium ultimum, Bipolaris sorokiniana, Barley Yellow Dwarf Virus, Brome Mosaic Virus, Soil Borne Wheat Mosaic Virus, Wheat Streak Mosaic Virus, Wheat Spindle Streak Virus, American Wheat Striate Virus, Claviceps purpurea, Tilletia tritici, Tilletia laevis, Ustilago tritici, Tilletia indica, Rhizoctonia solani, Pythium arrhenomannes, Pythium gramicola, 10 Pythium aphanidermatum, High Plains Virus, European wheat striate virus; Sunflower: Plasmophora halstedii, Sclerotinia sclerotiorum, Aster Yellows. Septoria helianthi, Phomopsis helianthi, Alternaria helianthi, Alternaria zinniae, Botrytis cinerea, Phoma macdonaldii, Macrophomina phaseolina, Erysiphe cichoracearum, Rhizopus oryzae, Rhizopus arrhizus, Rhizopus 15 stolonifer, Puccinia helianthi, Verticillium dahliae, Erwinia carotovorum DV. carotovora, Cephalosporium acremonium, Phytophthora cryptogea, Albugo tragopogonis; Corn: Fusarium moniliforme var. subglutinans, Erwinia stewartii, Fusarium moniliforme, Gibberella zeae (Fusarium graminearum), Stenocarpella maydi (Diplodia maydis), Pythium irregulare, Pythium debaryanum, Pythium graminicola, Pythium splendens, Pythium ultimum, 20 Pythium aphanidermatum, Aspergillus flavus, Bipolaris maydis O, T (Cochliobolus heterostrophus), Helminthosporium carbonum I. II & III (Cochliobolus carbonum), Exserohilum turcicum I, II & III, Helminthosporium pedicellatum, Physoderma maydis, Phyllosticta maydis, Kabatiella-maydis, 25 Cercospora sorghi, Ustilago maydis, Puccinia sorghi, Puccinia polysora, Macrophomina phaseolina, Penicillium oxalicum, Nigrospora oryzae. Cladosporium herbarum, Curvularia lunata, Curvularia inaequalis, Curvularia pallescens, Clavibacter michiganense subsp. nebraskense, Trichoderma viride. Maize Dwarf Mosaic Virus A & B, Wheat Streak Mosaic Virus, Maize

Chlorotic Dwarf Virus, Claviceps sorghi, Pseudonomas avenae, Erwinia chrysanthemi pv. zea, Erwinia carotovora, Corn stunt spiroplasma, Diplodia macrospora, Sclerophthora macrospora, Peronosclerospora sorghi, Peronosclerospora philippinensis, Peronosclerospora maydis.

Peronosclerospora sacchari, Sphacelotheca reiliana, Physopella zeae,
Cephalosporium maydis, Cephalosporium acremonium, Maize Chlorotic Mottle
Virus, High Plains Virus, Maize Mosaic Virus, Maize Rayado Fino Virus,
Maize Streak Virus, Maize Stripe Virus, Maize Rough Dwarf Virus; Sorghum:

- Exserohilum turcicum, Colletotrichum graminicola (Glomerella graminicola), Cercospora sorghi, Gloeocercospora sorghi, Ascochyta sorghina, Pseudomonas syringae p.v. syringae, Xanthomonas campestris p.v. holcicola, Pseudomonas andropogonis, Puccinia purpurea, Macrophomina phaseolina, Perconia circinata, Fusarium moniliforme, Alternaria alternata, Bipolaris
- sorghicola, Helminthosporium sorghicola, Curvularia lunata, Phoma insidiosa, Pseudomonas avenae (Pseudomonas alboprecipitans), Ramulispora sorghi, Ramulispora sorghicola, Phyllachara sacchari, Sporisorium reilianum (Sphacelotheca reiliana), Sphacelotheca cruenta, Sporisorium sorghi, Sugarcane mosaic H, Maize Dwarf Mosaic Virus A & B, Claviceps sorghi,
- 15 Rhizoctonia solani, Acremonium strictum, Sclerophthona macrospora,
 Peronosclerospora sorghi, Peronosclerospora philippinensis, Sclerospora
 graminicola, Fusarium graminearum, Fusarium oxysporum, Pythium
 arrhenomanes, Pythium graminicola, etc.

20

25 .

30

Nematodes include parasitic nematodes such as root-knot, cyst, lesion, and renniform nematodes, etc.

Insect pests include insects selected from the orders Coleoptera, Diptera, Hymenoptera, Lepidoptera, Mallophaga, Homoptera, Hemiptera, Orthoptera, Thysanoptera, Dermaptera, Isoptera, Anoplura, Siphonaptera, Trichoptera, etc., particularly Coleoptera and Lepidoptera. Insect pests of the invention for the major crops include: Maize: Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Helicoverpa zea, corn earworm; Spodoptera frugiperda, fall armyworm; Diatraea grandiosella, southwestern corn borer; Elasmopalpus lignosellus, lesser cornstalk borer; Diatraea saccharalis, surgarcane borer; Diabrotica virgifera, western corn rootworm; Diabrotica longicornis barberi, northern corn rootworm; Diabrotica undecimpunctata howardi, southern corn rootworm; Melanotus spp., wireworms; Cyclocephala borealis, northern masked chafer (white grub); Cyclocephala immaculata, southern masked chafer (white grub); Popillia japonica, Japanese beetle;

Chaetocnema pulicaria, corn flea beetle; Sphenophorus maidis, maize billbug; Rhopalosiphum maidis, corn leaf aphid; Anuraphis maidiradicis, corn root aphid; Blissus leucopterus leucopterus, chinch bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus sanguinipes, migratory grasshopper;

- 5 Hylemya platura, seedcorn maggot; Agromyza parvicornis, corn blot leafminer; Anaphothrips obscrurus, grass thrips; Solenopsis milesta, thief ant; Tetranychus urticae, twospotted spider mite; Sorghum: Chilo partellus, sorghum borer; Spodoptera frugiperda, fall armyworm; Helicoverpa zea, corn earworm; Elasmopalpus lignosellus, lesser cornstalk borer; Feltia subterranea, granulate
- cutworm; Phyllophaga crinita, white grub; Eleodes, Conoderus, and Aeolus spp., wireworms; Oulema melanopus, cereal leaf beetle; Chaetocnema pulicaria, corn flea beetle; Sphenophorus maidis, maize billbug; Rhopalosiphum maidis; corn leaf aphid; Sipha flava, yellow sugarcane aphid; Blissus leucopterus leucopterus, chinch bug; Contarinia sorghicola, sorghum
- midge; Tetranychus cinnabarinus, carmine spider mite; Tetranychus urticae, twospotted spider mite; Wheat: Pseudaletia unipunctata, army worm; Spodoptera frugiperda, fall armyworm; Elasmopalpus lignosellus, lesser cornstalk borer; Agrotis orthogonia, western cutworm; Elasmopalpus lignosellus, lesser cornstalk borer; Oulema melanopus, cereal leaf beetle;
- 20 Hypera punctata, clover leaf weevil; Diabrotica undecimpunctata howardi, southern corn rootworm; Russian wheat aphid; Schizaphis graminum, greenbug; Macrosiphum avenae, English grain aphid; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differentialis, differential grasshopper; Melanoplus sanguinipes, migratory grasshopper; Mayetiola destructor, Hessian
- fly; Sitodiplosis mosellana, wheat midge; Meromyza americana, wheat stern maggot; Hylemya coarctata, wheat bulb fly; Frankliniella fusca, tobacco thrips; Cephus cincius, wheat stem sawfly; Aceria tulipae, wheat curl mite; Sunflower: Suleima helianthana, sunflower bud moth; Homoeosoma electellum, sunflower moth; zygogramma exclamationis, sunflower beetle; Bothyrus gibbosus, carrot beetle; Neolasioptera murtfeldtiana, sunflower seed midge; Cotton: Heliothis
- beetle; Neolasioptera murtfeldtiana, sunflower seed midge; Cotton: Heliothis virescens, cotton budworm; Helicoverpa zea, cotton bollworm; Spodoptera exigua, beet armyworm; Pectinophora gossypiella, pink bollworm; Anthonomus grandis grandis, boll weevil; Aphis gossypii, cotton aphid; Pseudatomoscelis

seriatus, cotton fleahopper; Trialeurodes abutilonea, bandedwinged whitefly; Lygus lineolaris, tarnished plant bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differentialis, differential grasshopper; Thrips tabaci, onion thrips; Franklinkiella fusca, tobacco thrips; Tetranychus cinnabarinus, 5 carmine spider mite; Tetranychus urticae, twospotted spider mite; Rice: Diatraea saccharalis, sugarcane borer, Spodoptera frugiperda, fall armyworm; Helicoverpa zea, com earworm; Colaspis brunnea, grape colaspis; Lissorhoptrus oryzophilus, rice water weevil; Sitophilus oryzae, rice weevil; Nephotettix nigropictus, rice leafhopper; Blissus leucopterus leucopterus, chinch bug; Acrosternum hilare, green stink bug; Soybean: Pseudoplusia 10 includens, soybean looper; Anticarsia gemmatalis, velvetbean caterpillar; Plathypena scabra, green cloverworm; Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Spodoptera exigua, beet armyworm; Heliothis virescens, cotton budworm; Helicoverpa zea, cotton bollworm; Epilachna 15 varivestis, Mexican bean beetle; Myzus persicae, green peach aphid; Empoasca fabae, potato leafhopper; Acrosternum hilare, green stink bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differentialis, differential grasshopper; Hylemya platura, seedcorn maggot; Sericothrips variabilis. soybean thrips; Thrips tabaci, onion thrips; Tetranychus turkestani, strawberry spider mite; Tetranychus urticae, twospotted spider mite; Barley: Ostrinia 20 nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Schizaphis graminum, greenbug; Blissus leucopterus leucopterus, chinch bug; Acrosternum hilare, green stink bug; Euschistus servus, brown stink bug; Delia platura, seedcorn maggot; Mayetiola destructor, Hessian fly; Petrobia latens, brown 25 wheat mite; Oil Seed Rape: Brevicoryne brassicae, cabbage aphid; Phyllotreta cruciferae, Flea beetle; Mamestra configurata, Bertha armyworm; Plutella xylostella, Diamond-back moth; Delia ssp., Root maggots.

The present invention exploits the use of *Mlo* genes. The *Mlo* sequences provided herein can be utilized to alter the expression of native *Mlo* genes in plants. The *mlo* mutation confers recessive resistance to pathogens. Broad spectrum resistance in plants can be enhanced by defective *Mlo* genes.

30

While the invention is not bound by any model, *Mlo* could have a negative control function in leaf cell death. In this model, *Mlo* would suppress a

5

10

15

20

25

30

default cell suicide program in foliar tissue. Also, the MLO protein could have a specific negative regulatory function which works by down-regulating multiple disease-related functions. In this instance, spontaneous cell death in *mlo* mutant genotypes merely represents cell death because of accumulating activation of defense responses.

Several methods are available in the art for modulating the activity of *Mlo* genes. *Mlo* antisense sequences can be expressed in the plant cell. Such sequences will function to decrease expression of the maize *Mlo* genes as well as *Mlo* genes in other plants where the *Mlo* sequences share sequence identity.

It is recognized that with these nucleotide sequences, antisense constructions, complementary to at least a portion of the messenger RNA (mRNA) for the *Mlo* sequences can be constructed. Antisense nucleotides are constructed to hybridize with the corresponding mRNA. Modifications of the antisense sequences may be made as long as the sequences hybridize to and interfere with expression of the corresponding mRNA. In this manner, antisense constructions having 70%, preferably 80%, more preferably 85% sequence similarity to the corresponding antisensed sequences may be used. Furthermore, portions of the antisense nucleotides may be used to disrupt the expression of the target gene. Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or greater may be used.

The antisense construct may be proximal to the 5'-terminus or capping site, downstream from the capping site, between the capping site and the initiation codon and may cover all or a portion of the non-coding region. Additionally, the sequence may bridge the non-coding and coding region, be complementary to all or part of the coding region, to the 3'-terminus of the coding region, or complementary to the 3'-untranslated region of the mRNA.

It is recognized that the particular site to which the antisense sequence binds and the length of the antisense sequence will vary depending upon the degree of inhibition desired, the uniqueness of the sequence, the stability of the antisense sequence, and the like. See, for example, U.S. Patent Nos. 5,453,566; 5,530,192; and 5,728,926; all of which are herein incorporated by reference.

The nucleotide sequences of the present invention may also be used in the sense orientation to suppress the expression of endogenous genes in plants.

Methods for suppressing gene expression in plants using nucleotide sequences in the sense orientation are known in the art. The methods generally involve transforming plants with a DNA construct comprising a promoter that drives expression in a plant operably linked to at least a portion of a nucleotide sequence that corresponds to the transcript of the endogenous gene. Typically, such a nucleotide sequence has substantial sequence identity to the sequence of the transcript of the endogenous gene, preferably greater than about 65% sequence identity, more preferably greater than about 85% sequence identity, most preferably greater than about 95% sequence identity. See, U.S. Patent Nos. 5,283,184 and 5,034,323; herein incorporated by reference.

5

10

15

20

25

30

Individual *Mlo* genes or sets of *Mlo* genes can be rendered nonfunctional by mutagenesis. Such mutagenesis techniques include transposon disruption and recovery of such disruptions by reverse genetics approaches. Likewise, transformation-mediated mutagenesis may be utilized.

Disruption may be accomplished by transformation with gene replacement or gene truncation-disruption. See, for example, Bowen et al. (1995) Mol. Gen. Gent. 246:196-205; Walz et al. (1993) Curr. Gent. 25:421-427; Sweigard et al. (1992) Mol. Gen. Gent. 232:183-190; Hohn and Desjardins (1992) Mol. Plant Microbe Interact 5:249-256; Weber and Laitner (1994) Curr. Gent. 26:461-467; Templeton et al. (1994) Gene 142:141-146; Gorlach et al. (1998) Appl. Environ. Microbiol. 64:385-391; Schaeffer et al. (1994) Appl. Environ. Microbiol. 60:594-598; and the like, herein incorporated by reference. See also, Kempin et al. (1997) Nature 389:802-803 and Koncz et al. (1992) Plant Mol. Biol. 20:963-976.

Alternatively, the naturally occurring *Mlo* sequence or sequences may be modified by site-directed mutagenesis. Such methods may be utilized to induce specific alterations in targeted genes. One means for site-directed mutagenesis includes targeting modification or mutation of the *Mlo* sequences by homologous recombination. The method involves the use of RNA-DNA hybrid oligonucleotides. Such nucleotides exploit the natural recombinogenicity of RNA-DNA hybrids. The oligonucleotides are duplex oligonucleotides that share homology with at least one *Mlo* sequence. While any region of the *Mlo* sequence can be targeted, it may be preferable to target

5

10

15

20

25

30

the 5' region of the *Mlo* sequence. See, for example, U.S. Patent No, 5,565,350 that describes chimeric oligonucleotides useful for targeted gene correction for use in cultured mammalian cells; as well as U.S. provisional application Serial No. 06/065,628 drawn to gene manipulation in plant cells, herein incorporated by reference. Such methods can be used to alter or disrupt the ATG start codon for the gene.

Alternatively, protein coding regions of *Mlo* genes can be altered in such a manner that the gene products or proteins perform their function in a dominant negative manner resulting in a resistant phenotype. See, for example Krylov *et al.* (1997) *Proc. Natl. Acad. Sci. USA 94*:12274-12279.

Where the method of the invention relies upon the expression of an altered *Mlo* sequence or an *Mlo* antisense sequence in a plant, a number of promoters can be used. The promoters can be selected from constitutive and/or inducible promoters. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See, for example, Redolfi *et al.* (1983) *Neth. J. Plant Pathol.* 89:245-254; Uknes *et al.* (1992) *The Plant Cell* 4:645-656; and Van Loon (1985) *Plant Mol. Virol.* 4:111-116. See, also copending application entitled "Inducible Maize promoters", filed and herein incorporated by reference.

Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau et al. (1987) Plant Mol. Biol. 9:335-342; Matton et al. (1989) Molecular Plant-Microbe Interactions 2:325-331; Somsisch et al. (1986) Proc. Natl. Acad. Sci. USA 83:2427-2430; Somsisch et al. (1988) Molecular and General Genetics 2:93-98; and Yang, Y (1996) Proc. Natl. Acad. Sci. USA 93:14972-14977. See also, Chen et al. (1996) Plant J. 10:955-966; Zhang and Sing (1994) Proc. Natl. Acad. Sci. USA 91:2507-2511; Warner et al. (1993) Plant J. 3:191-201; Siebertz et al. (1989) Plant Cell 1:961-968; and the references cited therein. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen Fusarium moniliforme (see, for example, Cordero et al. (1992) Physiological and Molecular Plant Pathology 41:189-200).

Constitutive promoters include, for example, the core promoter of the Rsyn7 (copending application serial number 08/661,601), the 35S promoter, the core 35S promoter, and the like. Other constitutive promoters include, for example, U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597;

5 5,466,785; 5,399,680; 5,268,463; 5,608,142. See also, copending application entitled "Constitutive Maize Promoters" Provisional Application Serial No. 60/076,075 filed February 26, 1998, and herein incorporated by reference.

Tissue specific promoters include Yamamoto et al. (1997) Plant J. 12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803;

Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-168; Rinehart et al. (1996) Plant Physiol. 112(3):1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):525-535; Canevascini et al. (1996) Plant Physiol. 112(2):513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell. Differ. 20:181-196; Orozco et al. (1993) Plant Mol. Biol. 23(6):1129-1138; Matsuoka et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant J. 4(3):495-505.

The methods of the invention can be used with other methods for increasing pathogen resistance in plants. See, for example, Cai et al. (1997) Science 275:832-834; Roberts and Gallum (1984) J. Heredity 75:147-148; Ryerson and Heath (1996) Plant Cell 8:393-402 and Dangl et al. (1996) Plant Cell 8:1793-1807.

20

25

30

Altered *Mlo* sequences or antisense *Mlo* sequences of the invention can be introduced into any plant. The sequences to be introduced may be used in expression cassettes for expression in any plant of interest where expression in the plant cell is necessary. In other instances, such as for recombination, oligonucleotides are synthesized, purified and introduced into the plant cell.

Where expression cassettes are needed, such expression cassettes will comprise a transcriptional initiation region linked to the coding sequence or antisense sequence of the nucleotide of interest. Such an expression cassette is provided with a plurality of restriction sites for insertion of the sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.

The transcriptional initiation region, the promoter, may be native or analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By foreign is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced. As used herein a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

While it may be preferable to express the sequences using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of a MLO protein in the plant or plant cell. Thus, the phenotype of the plant or plant cell is altered.

10

15

20

25

30

The transcriptional cassette will include in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a DNA sequence of interest, and a transcriptional and translational termination region functional in plants. The termination region may be native with the transcriptional initiation region, may be native with the DNA sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also, Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen et al. (1990) Plant Cell. 2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; Joshi et al. (1987) Nucleic Acid Res. 15:9627-9639.

Nucleotide sequences of the invention are provided in expression cassettes for expression in the plant of interest. The cassette will include 5' and 3' regulatory sequences operably linked to the sequence of interest. The cassette may additionally contain at least one additional sequence to be cotransformed into the organism. Alternatively, the additional sequence(s) can be provided on another expression cassette.

Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, Campbell

5

10

15

20

25

30

and Gowri (1990) *Plant Physiol. 92*:1-11 for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Patent Nos. 5,380,831, 5,436,391, and Murray *et al.* (1989) *Nucleic Acids Res. 17*:477-498, herein incorporated by reference.

Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

The expression cassettes may additionally contain 5' leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et al. (1989) PNAS USA 86:6126-6130); potyvirus leaders, for example. TEV leader (Tobacco Etch Virus) (Allison et al. (1986); MDMV leader (Maize Dwarf Mosaic Virus); Virology 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP), (Macejak et al. (1991) Nature 353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987) Nature 325:622-625); tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al. (1991) Virology 81:382-385). See also, Della-Cioppa et al. (1987) Plant Physiol. 84:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Towards this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in

vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g. transitions and transversions, may be involved.

5

10

15

20

25

30

The sequences of the present invention can be used to transform or transfect any plant. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained. Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (Crossway et al. (1986) Biotechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606, Agrobacterium-mediated transformation (Townsend et al., U.S. Pat No. 5,563,055), direct gene transfer (Paszkowski et al. (1984) EMBO J. 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford et al., U.S. Patent No. 4,945,050; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); and McCabe et al. (1988) Biotechnology 6:923-926). Also see Weissinger et al. (1988) Ann. Rev. Genet. 22:421-477; Sanford et al. (1987) Particulate Science and Technology 5:27-37 (onion); Christou et al. (1988) Plant Physiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology 6:923-926 (soybean); Finer and McMullen (1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soybean); Datta et al. (1990) Biotechnology 8:736-740 (rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309 (maize); Klein et al. (1988) Biotechnology 6:559-563 (maize); Tomes, U.S. Patent No. 5,240,855; Buising et al., U.S. Patent Nos. 5,322,783 and 5,324,646; Tomes et al. (1995) 'Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg (Springer-Verlag, Berlin) (maize); Klein et al. (1988) Plant Physiol. 91:440-444 (maize); Fromm et al. (1990) Biotechnology 8:833-839 (maize); Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764; Bowen et al., U.S. Patent No. 5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA

84:5345-5349 (Liliaceae); De Wet et al. (1985) in The Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, New York), pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl. Genet. 84:560-566 (whisker-mediated transformation); D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports 12:250-255 and Christou and Ford (1995) Annals of Botany 75:407-413 (rice); Osjoda et al. (1996) Nature Biotechnology 14:745-750 (maize via Agrobacterium tumefaciens); all of which are herein incorporated by reference.

5

10

15

20

25

30

The modified plant may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell. Reports, 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved.

The *Mlo* sequences of the invention are also useful as molecular markers. Such markers are useful in breeding programs, particularly those aimed at improving disease resistance. The maize *Mlo* sequences have been mapped to chromosome locations and these positions related to known disease resistance loci.

The present invention provides a method of genotyping a plant comprising a polynucleotide of the present invention. Preferably, the plant is a monocot, such as maize or sorghum. Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population. Molecular marker methods can be used for phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map based cloning, and the study of quantitative inheritance. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Chapter 7, Clark, Ed., Springer-Verlag, Berlin (1997). For molecular marker methods, see generally, The DNA Revolution by Andrew H. Paterson (1996)

(Chapter 2) in: Genome Mapping in Plants (ed. Andrew H. Paterson) by Academic Press/R. G. Landis Company, Austin, Texas, pp. 7-21.

5

10

15

20

25

30

The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymorphisms (RFLPs). RFLPs are the product of allelic differences between DNA restriction fragments caused by nucleotide sequence variability. As is well known to those of skill in the art, RFLPs are typically detected by extraction of genomic DNA and digestion with a restriction enzyme. Generally, the resulting fragments are separated according to size and hybridized with a probe; single copy probes are preferred. Restriction fragments from homologous chromosomes are revealed. Differences in fragment size among alleles represent an RFLP. Thus, the present invention further provides a means to follow segregation of a gene or nucleic acid of the present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis. Linked chromosomal sequences are within 50 centiMorgans (Cm), often within 40 or 30 Cm, preferably within 20 or 10 Cm, more preferably within 5, 3, 2, or 1 Cm of a gene.

In the present invention, the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize, under selective hybridization conditions, to a gene encoding a polynucleotide of the present invention. In preferred embodiments, the probes are selected from polynucleotides of the present invention. Typically, these probes are cDNA probes or *PstI* genomic clones. The length of the probes is discussed in greater detail, *supra*, but are typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length. Preferably, the probes are single copy probes that hybridize to a unique locus in a haploid chromosome complement. Some exemplary restriction enzymes employed in RFLP mapping are EcoRI, EcoRv, and SstI. As used herein the term "restriction enzyme" includes reference to a composition that recognizes and, alone or in conjunction with another composition, cleaves at a specific nucleotide sequence.

The method of detecting an RFLP comprises the steps of (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present of said genomic DNA; (c) detecting therefrom a RFLP. Other methods of differentiating polymorphic (allelic) variants of polynucleotides of the present invention can be had by utilizing molecular marker techniques well known to those of skill in the art including such techniques as: 1) single-stranded conformation analysis (SSCP); 2) denaturing gradient gel electrophoresis (DGGE); 3) Rnase protection assays; 4) allelespecific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the E. coli mutS protein; and 6) allele-specific PCR. Other approaches based on the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGE); heteroduplex analysis (HA); and chemical mismatch cleavage (CMC). Exemplary polymorphic variants are provided in Table I, supra. Thus, the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a polynucleotide of the present invention with a nucleic acid probe. Generally, the sample is a plant sample; preferably, a sample suspected of comprising a maize polynucleotide of the present invention (e.g., gene, mRNA). The nucleic acid probe selectively hybridizes, under stringent conditions, to a subsequence of a polynucleotide of the present invention comprising a polymorphic marker. Selective hybridization of the nucleic acid probe to the polymorphic marker nucleic acid sequence yields a hybridization complex. Detection of the hybridization complex indicates the presence of that polymorphic marker in the sample. In preferred embodiments, the nucleic acid

The following examples are offered by way of illustration and not by way of limitation.

probe comprises a polynucleotide of the present invention.

30

25

5

10

15

20

EXPERIMENTAL

Mlo Sequences

5

10

15

20

25

30

Eight maize Mlo homologue sequences have been identified. The nucleotide sequences (SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15) and amino acid sequences (SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16) are provided. DNA sequence analysis was performed according to Sambrook et al. (1989) Mol. Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Plainview, New York). The maize Mo homologue/orthologue cDNA sequences were identified from mRNA isolated from various maize tissues and used to make cDNAs that are then cloned into vectors, usually pSPORT1. These cDNA libraries are EST sequenced via standard dye-fluorescence labeling and ABI machine electrophoresis and image capture. The Mlo homologues were identified by their blast score identity to the barley HvMLO1 published sequence. These maize clones, in particular the longest members of each contig or gene, were obtained and additional sequencing was done on them using oligonucleotide primers designed to internal portions of the cDNA and dye-fluorescence labeling and ABI machine electrophoresis and image capture. The complete edited sequences were assembled and analyzed.

The sequences from maize show sequence similarity to the published barley *Mlo* sequence as provided in Tables 1 and 2. Figure 1 provides a sequence alignment for the maize *Mlo* homologues with the barley *Mlo* sequence designated as Hv*Mlo*1. Figure 2 groups the *Mlo* sequences based on relatedness as well as the plant tissue from which it was isolated.

The ZmMLO genes were mapped by RFLP analysis using Southern blots of genomic DNA isolated from F2 and F3 and F4 segregating maize populations. The DNA was isolated using a modified CTAB adapted from the CERES RFLP Lab Manuel based on the Saghai-Mahoof procedure (Saghai-Mahoof et al. (1984) Proc. Natl. Acad. Sci. USA 81:8014-8018). Genomic DNA was cut with four restriction enzymes BamH1, EcoR1, EcoRV, and HindIII and run (5µg/lane) on 0.8% TAE agarose gels for 800 volt-hours. The gels were Southern blot transferred to Hybond-N membrane (Amersham Life Science), baked and UV-crosslinked. The ZmMLO cDNA inserts were liberated from its vector by cleaving with two restriction enzymes, usually Sall

and *Not*I, and the insert was purified from agarose gels following electrophoresis. The clone was random prime labeled with ³²P-dCTP using the RTS (Gibco BRL) labeling kit. The cDNA inserts were used to probe parental screening blots to identify a mapping population with a RFLP polymorphism.

5 Once a polymorphism was identified, the inserts were used to probe mapping blots containing DNA from segregating individuals. The map position was determined using MAPMAKER/EXP 3.0 (Lander et al (1987) Genomics 1:174-181) by scoring 86 segregating progeny as homozygous parent A, as homozygous parent B, or as heterozygous. The map position was assigned to an existing core RFLP map of either of the following three populations: ALEB9 (240 individuals) DRAG2 (283 individuals) or MARS (1075 individuals). Table 3 shows the association of maize Mlo homologues and disease related loci and QTLS.

BestFit (Similarity/Identity)

| \$ | | | | | | | | | | |
|----------------------|-------------------|---------|-------|--------|----------|-------------|------------|-----------|----------|------------------|
| Zm <i>MLO</i> 9 | | 37 | 39 | \$ | 46 | 4 | 39 | 4 | 43 | %00I |
| Zm <i>MLO</i> 8 | | 44 | 43 | 46 | 4 | 92 | 43 | 99 | %00I | 99 |
| Zm <i>MLO1</i> | | 40 | 39 | 43 | 39 | 20 | 14 | %001· | 64 | . 51 |
| ZmAILO6 | 8 | 28 | 51 | 58 | 38 | 45 | %001 | 22 | 54 | 20 |
| Zm <i>MLO</i> 5 | rity/Identity) to | 45 | 38 | 48 | 46 | %001 | 51 | 58 | ~ | 26 |
| Zm <i>MLO</i> 4 | rotein (Simila | 35 | 35 | 40 | 100% | 56 | 48 | | 52 | . 15 |
| Znn <i>AlLO</i> 2 | هـ. | 53 | 45 | %001 | 49 | 26 | 99 | 22 | 95 | 49 |
| ZmA1LO1 | | 29 | 100% | 56 | 44 | 47 | : 15 | 49 | * | 48 |
| IIvMLO! | | 100% | 77 | : 5 | 47 | 54 | : % | . 84 | 2 7 | 4 8 8 |
| Maize MLO Gene | | HvMI OI | 10 IV | ZmWI O | Zm.M. 04 | 7mM/05 | 2m/M 06 | 7 m/// 07 | 2mm201 | SmML09 |

Gap (Similarity/Identity)

| 8 ZmMLO9 | | 32 | 28 | 34 | 42 | 36 | 36 | 40 | . 40 | 100% |
|----------------|--------------------|---------|--------|--------|-----------|-------|--------|--------------------|---------|---------|
| ZmMLO8 | | 40 | 37 | 45 | 37 | 09 | 4 | 51 | 100% | 51 |
| ZmML07 | | 36 | 28 | 39 | 35 | 42 | 40 | 100% | 59 | 44 |
| 3mMLO6 | | 55 | 43 | 57 | 34 | 43 | 100% | 51 | 52 | 46 |
| ZmMLO5 | entity) to: | 33 | 32 | 36 | 32 | %001 | 49 | 48 | 29 | 48 |
| ZmMLO4 | ogy (Similarity/Id | 31 | 24 | 36 | 100% | 38 | 43 | 43 | 49 | . 23 |
| ZmML02 | Protein Homolo | .43 | 36 | 100% | 46 | 42 | 64 | 47 | 54 | 42 |
| ZmMLO1 | | 99 | %001 | 46 | : [- | . 80 | 51 | 35: | 48 | 36 |
| HvMLOI | | 100% | 71 | . 5 | 42 | 7 07 | 2 % | 43 | 40 | 64 |
| Maize MLO Gene | | HvMI O1 | 10 MmZ | 7mMCO1 | Zm1/11.04 | ZmMOS | 7mM/O6 | ZmintCO ZmMI O7 | 7mM/108 | ZmWI.O9 |

TABLE 3
Association of Maize MLO Homologues and Disease Related Loci and QTLs

| Maize MLO Homologue | Ž | Nearby Disease Resistance Loci or QTLs |
|---------------------|--------|--|
| ZmMLO1 1.01 | 1.01 | European Corn Borer QTL |
| | 1.01/2 | Northern Corn Leaf Blight QTL |
| ZmMLO2 1.04 | 1.03/6 | Northern Corn Leaf Blight QTL |
| | 1.04 | Gray Leaf Spot QTL |
| | 1.04 | Maize Streak Virus (msvl) |
| | 1.05 | Stewart's Wilt QTL |
| ZmMLO4 3.05 | 3.04/5 | European Corn Borer QTL |
| | 3.04/5 | Gibberella Stalk Rot QTL |
| ZmMLO5 3.06 | 3.07/8 | Northern Corn Leaf Blight QTL |
| ZmMLO6a 5.05 | 5.04 | Gibberella Stalk Rot QTL |
| | 5.06 | Northern Corn Leaf Blight QTL |
| ZmMLO6b 6.02/3 | 6.01 | Southern Corn Leaf Blight (rhm1) |
| ZmMLO7 6.05/7 | | |
| ZmMLO8 9.04 | 9.05 | Southwestern Corn Borer QTL |
| | | |
| ZmMLO9 na | | |

TABLE 4

Mutator Insertion Mutants of ZmMLO Homologues (TUSC)

| ZmML02 | |
|-----------------|--|
| PV03 81D3 | C. heterostrophus intermediate resistance (segregating as recessive) |
| PV03 81D2 (sib) | C. heterostrophus intermediate resistance (segregating as recessive) |

| C. heterostrophus intermediate resistance (segregating as recessive) | C. heterostrophus resistance (segregating as recessive) |
|--|---|
| PV03 108B1 | PV03 108A1 (sib) |
| | |

BT94 5F11 (". heterostrophus resistance (segregating as recessive); also leaf necrosis

The Trait Utility System for corn (TUSC) system was utilized to generate transposon mutants in the *Mlo* sequences in maize. The combination of transposon mutagenesis via *Mutator* and PCR-based selection of target-specific *Mu* insertions makes up the TUSC system. See, for example, Benson *et al.* (1995) *Plant Cell.* 7:75-84; Mena *et al.* (1996) *Science 274*:1537-1540; U.S. Patent Application No. 08/835,638 and U.S. Patent Application No. 08/262,056; all of which are herein incorporated by reference. Table 4 shows *Mutator* insertion mutants of Zm*Mlo* homologues.

Oligonucleotide primers based on Mlo maize sequences were designed and paired with Mu TIR primer in PCR reactions. The products of the screening process identify individuals in the collection having Mu elements inserted into Mlo sequences.

The gene-specific primers used for TUSC of ZmMLO2 are: 19005, 5'-AGTTATCCAAGGCATGCCGGTGGTAAAACT-3' (SEQ ID NO18); and 19007, 5'-AAGTCATCGAGGGAGGCATCACTTACAG-3' (SEQ ID NO:19). For TUSC the mutator-element specific primer used was: 9242, 5'-

- AGAGAAGCCAACGCCA(AT)CGCCTC(CT)ATTTCGTC-3' (SEQ ID NO:20). Seven positive "hits" to ZmMLO2 were identified. Twenty F2 seeds for each of the hits were planted in the greenhouse and screened as follows. Seeds were planted in trays, containing 2-inch wells for each seed, in Strong-Lite (circleR) Universal Mix potting soil (Universal Mix, Pine Bluff, Arkansas, U.S.A.) and grown in a greenhouse (16 hour day,
- 20 20.6-34.8°C, 50% average RH, 560-620 microEinsteins, of light both sun and halogen lamps, averaging 25 heat units per day. Plants were grown for 14-18 days until the V5 stage (ca. 25cm height) and inoculated with spores of Cochliobolus heterostrophus (Drechs.) Dreshs. Race 0, also known as Bipolaris maydis (Southern Leaf Blight) and Cochliobolus carbonum R. R Nelson, also known as Bipolaris zeicola (Helminthosporium)
- 25 Leaf Spot). For general leaf inoculation, spore suspensions of 4 x 10⁴ per ml of 0.02% Tween-20 were sprayed as an aerosol on the leaves. Approximately 0.5 ml were applied per leaf late in the afternoon. The plants were then immediately covered with a plastic tent and kept at R.T. in order to enhance humidity and spore germination. The plastic tent was removed early in the morning, and the plants were returned to the greenhouse for the duration of the experiment, usually three days. Susceptibility to Cochliobolus carbonum
- was determined by either increased size or number of lesions. Resistance to Cochliobolus

heterostrophus was determined by either reduced size or number of lesions. Lesion mimics were also investigated; these mutations form spontaneous lesions in the absence of pathogen attach. Other phenotypes affecting growth and development were also noted.

TABLE 5

| Maize MLO Gene | ZmML01 | ZmML02 | ZmMLO4 | ZmMLO5 | Zm <i>MLO</i> 6a | ZmMLO6b | ZmML07 | ZmMLO8 | ZınMLO9 |
|-------------------------------------|----------------|----------------|------------|----------|------------------|-----------|------------|-----------|------------|
| Gene Mapping Information | | | | | | | | | |
| Gene Complexity on Southern blot | | _ | <u></u> . | guing. | | 2 · | - | 1,2 | 1,2 |
| Chromosome location (bin) | 1.01 | 1.04 | 3.05 | 3.06 | 5.05 | 6.02/3 | 9.04 | 6.05/7 | unassigned |
| Chromosome location (arm) | 2 | SI | 31 | 31 | 5L | 79 | . 16 | 79 | |
| Nearby Public Marker | Bn15.62 | BnI12.06 | umc10 | bn110.24 | umc43 | umc113 | umc95 | bn15.47 | |
| Distance from Public Marker | 12.3 (down) | 10.1 (down) | 6.5 (down) | 1.3 (up) | 10.9 (down) | 52.0 (up) | 6.3 (down) | 10.1 (up) | |
| Distance | 15 | 5.9 | 35.2 | 1.3 | 1.8 | 52 | 10.7 | 10.1 | |
| LOD Score | 18.2 | 24.1 | 21.3 | 31.7 | 35.2 | 4.6 | 36.5 | 23.8 | |
| RFLP Restriction Enzyme | EcoRI | HindIII | EcoRV | EcoRI | BamHI | BamHI | HindIII | EcoRV | |
| Mapping Population | ALEB9 | ALEB9 | DRAG2 | ALEB9 | DRAG2 | DRAG2 | DRAG2 | DRAG2 | DRAG2 |
| Mapping Parents (Public Names) | R67/P38 | R67/P38 | 17J/MWO | R67/P38 | 17J/MWO | 17J/MWO | 17J/MWO | 17J/MWO | 17J/MW0 |

| | • | |
|---|---|---|
| C | 1 | ٠ |
| - | | , |
| ٠ | - | |
| 4 | 7 | |
| | | |
| • | ◁ | |
| F | | |
| | | |

| Maize MLO Gene | Hv <i>MLO</i> 1 | ZmMLO Z | ZmML02 | ZmMLO2 ZmMLO4 | ZmMLO5 | ZmMLO5 ZmMLO6 | ZmML07 | ZmMLO8 | ZmML09 |
|------------------------------------|-----------------|------------|--------|---------------|--------|---------------|----------------|----------------|--------|
| Protein Structure Predictions | | • | | | • | | | | |
| Number of amino acids | 533 | 224+ | 595 | 509 | 149+ | 515 | 499 | 492 | +69+ |
| Calculated molecular weight | 60,408 | | 64,274 | 58,613 | | 56,980 | 908'99 | 55,500 | |
| Calculated pl | 2.6 | | 9.6 | 9.3 | | 9.5 | 8.9 | 9.3 | |
| Number of transmembrane domains | 6 or 7 | | 6 or 7 | 6 or 7. | | 6 or 7 | 6 or 7 | 6 or 7 | |
| Glycosylation sites? Asn-X-Ser/Thr | 0 | 0 . | - | . 3 | 2 | _ | - | 0 | |
| Signal Peptide | ž | % | Š. | Š | No | Š | S _o | N _o | Š |

Example 1: Transformation and Regeneration of Transgenic Plants

Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing the ZmMLO1 antisense sequence operably linked to the ubiquitin promoter (Figure 3). This plasmid also contains the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25-37) that confers resistance to the herbicide Bialophos. Transformation is performed as follows. All media recipes are in the Appendix.

Preparation of Target Tissue

The ears are surface sterilized in 30% Chlorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5-cm target zone in preparation for bombardment.

15

10

Preparation of DNA

A plasmid vector comprising the PAT selectable marker and the *ZmMlo1* antisense sequence operably linked to a the ubiquitin is made and precipitated onto 1.1 µm (average diameter) tungsten pellets using a CaCl₂ precipitation procedure as follows:

20

100 μl prepared tungsten particles in water 10 μl (1 μg) DNA in TrisEDTA buffer (1 μg total) 100 μl 2.5 M CaCl₂ 10 μl 0.1 M spermidine

25

30

Each reagent is added sequentially to the tungsten particle suspension, while maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid removed, washed with 500 ml 100% ethanol, and centrifuged for 30 seconds. Again the liquid is removed, and 105 µl 100% ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the

tungsten/DNA particles are briefly sonicated and 10 µl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment.

Particle Gun Treatment

5

10

15

20

The sample plates are bombarded at level #4 in particle gun #HE34-1 or #HE34-2. All samples receive a single shot at 650 PSI, with a total of ten aliquots taken from each tube of prepared particles/DNA.

Subsequent Treatment

Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. After approximately 10 weeks of selection, selection-resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone-free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5" pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored and scored for enhanced disease resistance as a result of antisense disruption of ZmMlo1 function.

APPENDIX

272 V

| Ingredient | Amount | Unit |
|-------------------------------|---------|------|
| D-I H ₂ O | 950.000 | Ml |
| MS Salts (GIBCO 11117-074) | 4.300 | G |
| Myo-Inositol | 0.100 | G |
| MS Vitamins Stock Solution ## | 5.000 | Ml |
| Sucrose | 40.000 | G |
| Bacto-Agar @ | 6.000 | G |

Directions:

- @ = Add after bringing up to volume
 Dissolve ingredients in polished D-I H₂O in sequence
 Adjust to pH 5.6
 Bring up to volume with polished D-I H₂O after adjusting pH
 Sterilize and cool to 60°C.
- ## = Dissolve 0.100 g of Nicotinic Acid; 0.020 g of Thiamine.HCL; 0.100 g of Pyridoxine.HCL; and 0.400 g of Glycine in 875.00 ml of polished D-I H₂O in sequence. Bring up to volume with polished D-I H₂O. Make in 400 ml portions. Thiamine.HCL & Pyridoxine.HCL are in Dark Desiccator. Store for one month, unless contamination or precipitation occurs, then make fresh stock.
- 15 Total Volume (L) = 1.00

288 J

| Ingredient | Amount | Unit |
|-------------------------------|---------|------|
| D-I H₂O | 950.000 | Ml |
| MS Salts | 4.300 | g |
| Myo-Inositol | 0.100 | g |
| MS Vitamins Stock Solution ## | 5.000 | ml |
| Zeatin .5mg/ml | 1.000 | ml |
| Sucrose | 60.000 | g |
| Gelrite @ | 3.000 | g |
| Indoleacetic Acid 0.5 mg/ml # | 2.000 | ml |
| 0.1mM Abscisic Acid | 1.000 | ml |
| Bialaphos 1mg/ml # | 3.000 | ml |

Directions:

- @ = Add after bringing up to volume
- 5 Dissolve ingredients in polished D-I H₂O in sequence

Adjust to pH 5.6

Bring up to volume with polished D-I H₂O after adjusting pH Sterilize and cool to 60°C.

Add 3.5g/L of Gelrite for cell biology.

- ## = Dissolve 0.100 g of Nicotinic Acid; 0.020 g of Thiamine.HCL; 0.100 g of Pyridoxine.HCL; and 0.400 g of Glycine in 875.00 ml of polished D-I H₂O in sequence. Bring up to volume with polished D-I H₂O. Make in 400 ml portions. Thiamine.HCL & Pyridoxine.HCL are in Dark Desiccator. Store for one month, unless contamination or precipitation occurs, then make fresh stock.
- Total Volume (L) = 1.00

560 R

| Ingredient | Amount | Unit |
|--|---------|------|
| D-I Water, Filtered | 950.000 | ml |
| CHU (N6) Basal Salts (SIGMA C-1416) | 4.000 | g |
| Eriksson's Vitamin Mix (1000X SIGMA-1511 | 1.000 | ml |
| Thiamine.HCL 0.4mg/ml | 1.250 | ml |
| Sucrose | 30.000 | g |
| 2, 4-D 0.5mg/ml | 4.000 | ml |
| Gelrite @ | 3.000 | g |
| Silver Nitrate 2mg/ml # | 0.425 | ml |
| Bialaphos 1mg/ml # | 3.000 | ml |

Directions:

@ = Add after bringing up to volume
 # = Add after sterilizing and cooling to temp.

Dissolve ingredients in D-I H₂O in sequence

Adjust to pH 5.8 with KOH

Bring up to volume with D-I H₂O

- 10 Sterilize and cool to room temp.
 - Total Volume (L) = 1.00

560 Y

| Ingredient | Amount | Unit |
|--|---------|------|
| D-I Water, Filtered | 950.000 | ml |
| CHU (N6) Basal Salts (SIGMA C-1416) | 4.000 | g |
| Eriksson's Vitamin Mix (1000X SIGMA-1511 | 1.000 | ml |
| Thiamine.HCL 0.4mg/ml | 1.250 | ml |
| Sucrose | 120.000 | g |
| 2,4-D 0.5mg/ml | 2.000 | ml |
| L-Proline | 2.880 | g |
| Gelrite @ | 2.000 | g |
| Silver Nitrate 2mg/ml # | 4.250 | ml |

Directions:

- @ = Add after bringing up to volume.
- 5 # = Add after sterilizing and cooling to temp.

Dissolve ingredients in D-I H₂O in sequence

Adjust to pH 5.8 with KOH

Bring up to volume with D-I H₂O

Sterilize and cool to room temp.

10 ** Autoclave less time because of increased sucrose**

Total Volume (L) = 1.00

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

5

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims

INDICATIONS RELATING TO DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL

(PCT Rule 13bis)

| A. | The indications made below relate to the deposited microorganism 11-20 | or other biological material referred to in the description on page 5, lines |
|-----------|--|--|
| B. | IDENTIFICATION OF DEPOSIT | Further deposits are identified on an additional sheet |
| | ne of depository institution American Type Culture Collect | ction |
| Add | ress of depositary institution (including postal code and country) | |
| | Manassa, Virginia USA | |
| | | |
| Date | e of deposit | Accession Numbers 98725-98729 |
| C. | ADDITIONAL INDICATIONS (leave blank if not applicable) | This information is continued on an additional sheet |
| | | |
| D. | DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE | (if the indicators are not for all designated States) |
| | | |
| E. | SEPARATE FURNISHING OF INDICATIONS (leave blank if not app | olicable) |
| The Nu | Indications listed below will be submitted to the International Bureau or mber of Deposit*) | later (specify the general nature of the indications e.g., "Accession |
| | Date of Deposit | |
| | • | |
| | For receiving Office use only | For International Bureau use only |
| | This sheet was received with the international application | This sheet was received with the International Bureau on: |
| Au | thorized-officer | Authorized officer |

WHAT IS CLAIMED IS:

- 1. A method for creating or enhancing disease resistance in a plant, said method comprising modulating the expression of an *Mlo* nucleotide sequence wherein said nucleotide sequence is selected from the group consisting of:
 - (a) a nucleotide sequence encoding a maize Mlo gene;
- (b) a nucleotide sequence encoding at least one of the maize MLO amino acid sequences selected from the group consisting of the sequences set forth in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16;
- (c) a nucleotide sequence comprising at least one of the nucleotide sequences set forth in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15;
- (d) a nucleotide sequence selected from the group consisting of sequences deposited in the American Type Culture Collection as Accession Nos. 98725, 98726, 98727, 98728, and 98729;
- (e) a nucleotide sequence that encodes an antisense sequence corresponding to a sequence of a), b), c) or d);
- (f) a nucleotide sequence which hybridizes under stringent conditions to one of the nucleotide sequences set forth in a), b), c), d) or e).
- 2. The method of claim 1, wherein said modulation comprises decreasing the expression of the *Mlo* sequence.
 - 3. The method of claim 1, wherein said plant is a monocot.
 - 4. The method of claim 3, wherein said monocot is maize.
- 5. A modified plant having altered levels of an MLO protein wherein said plant has stably incorporated into its genome a DNA construct, wherein said DNA construct comprises a nucleotide sequence operably linked

to a promoter capable of regulating transcription of said sequence in said plant, wherein said nucleotide sequence is selected from the group consisting of:

- (a) a nucleotide sequence encoding a maize Mlo gene;
- (b) a nucleotide sequence encoding at least one of the maize MLO amino acid sequences selected from the group consisting of the sequences set forth in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16;
- (c) a nucleotide sequence comprising at least one of the nucleotide sequences set forth in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15;
- (d) a nucleotide sequence selected from the group consisting of sequences deposited in the American Type Culture Collection as Accession Nos. 98725, 98726, 98727, 98728, and 98729;
- (e) a nucleotide sequence that encodes an antisense sequence corresponding to a sequence of a), b), c) or d);
- (f) a nucleotide sequence which hybridizes under stringent conditions to one of the nucleotide sequences set forth in a), b), c), d) or e).
- 6. The modified plant of claim 5, wherein said plant exhibits a decrease in the expression of a *Mlo* gene.
 - 7. The modified plant of claim 5, wherein said plant is a monocot.
 - 8. The modified plant of claim 7, wherein said monocot is maize.
- 9. The maize plant of claim 8, wherein said plant has decreased levels of the *Mlo* protein.
- 10. The maize plant of claim 8, wherein said maize plant comprises an insertion sequence in at least one maize *Mlo* gene.
 - 11. Seed of the plant of any one of claims 5, 6, 7, 8, 9, and 10.

12. An isolated MLO protein, wherein said protein comprises an amino acid sequence selected from the group consisting of the MLO amino acid sequences set forth in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16.

- 13. An isolated nucleotide sequence said sequence selected from the group consisting of:
 - (a) a nucleotide sequence encoding a maize Mlo gene;
 - (b) a nucleotide sequence encoding at least one of the maize MLO amino acid sequences selected from the group consisting of the sequences set forth in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16;
 - (c) a nucleotide sequence comprising at least one of the nucleotide sequences set forth in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15;
 - (d) a nucleotide sequence selected from the group consisting of sequences deposited in the American Type Culture Collection as Accession Nos. 98725, 98726, 98727, 98728, and 98729;
 - (e) a nucleotide sequence that encodes an antisense sequence corresponding to a sequence of a), b), c) or d);
 - (f) a nucleotide sequence which hybridizes under stringent conditions to one of the nucleotide sequences set forth in a), b), c), d) or e).
- 14. A modified plant cell having an altered level of an MLO protein wherein said plant cell has stably incorporated into its genome a DNA construct, wherein said DNA construct comprises a nucleotide sequence operably linked to a promoter capable of regulating transcription of said sequence in said plant cell, wherein said nucleotide sequence is selected from the group consisting of:
 - (a) a nucleotide sequence encoding a maize Mlo gene;
 - (b) a nucleotide sequence encoding at least one of the maize MLO amino acid sequences selected from the group consisting of the sequences set forth in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16;
 - (c) a nucleotide sequence comprising at least one of the nucleotide sequences set forth in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15;

(d) a nucleotide sequence selected from the group consisting of sequences deposited in the American Type Culture Collection as Accession Nos. 98725, 98726, 98727, 98728, and 98729;

- (e) a nucleotide sequence that encodes an antisense sequence corresponding to a sequence of a), b), c) or d);
- (f) a nucleotide sequence which hybridizes under stringent conditions to one of the nucleotide sequences set forth in a), b), c), d) or e).
- 15. The modified plant cell of claim 14, wherein said cell exhibits a decrease in the expression of an *Mlo* gene.
 - 16. The modified plant cell of claim 14, wherein said cell is from a monocot.
- 17. The modified plant cell of claim 16, wherein said monocot is maize.

| 4 IE |
|--|
| 1/5 CLUSTAL V (1.7) Multiple Sequence Alignments of HvMLO1 and 9 ZmMLO Homologues |
| HVMLO1-MSDKKGVPARELPETPSWAVAVVFAAMVLVSVLMEHGLHKLGHWFQHRHKKALWEALEKZMMLO1 |
| ZMMLO2MGGDGTRALDQTPTWAVAAVCAVIVAASILLEGFLHHLGQLLNKKRKKALFDALEK ZMMLO6MGGGGGGNSRELDDTPTWAVASVCGVIVLISILLEKGLHHVGEFFSHRKKKAMVEALEK |
| ZmmLOZMGKEATLAFTPTWVVAIVCLVIVSISLAAERSLHYLGKYLECKKQKALFSALQR |
| 5 MM OB MAAEGEAAALEFTPTWIVAAVCSLIVLLSLVAERCLHYLGKTLKRKNQKPLFEALLK |
| ZmML09MAAEQGRSLAETPTWSVATVTTLMVAACFLVERSLSRFAKWLRKTKRKAMLAALEK Regions[N-Terminus] [TM Helix 1] [Intervening Region 1- |
| HMLO1 MKAELMLVGFISLLLIVTQDPIIAKICISED-AADVMWPCKRGTEGRKPS |
| ZMMLO1ZMMLO2 VKSELMTLGFISLLLTVTGR-YIARICIPEG-AANTMLPCRLSGHSVAEEPKGHGRRZMMLO6 VKAELMVLGFISLLLVFGQN-YIIKVCISNH-AANTMLPCKLEAAAVEGK-DGHGKEAAA |
| ZmmLO7 LKEELMLLGF1SFVLSLSQG-F1VS1CIPET-STDFMLPCNRGNSZmMLO5GNS |
| ZmmlO8VKEELMLLGFISLLLTVFQG-MIRRTCIPER-VTFHMLPCEKPDEKAGEAATMEHFVGTL |
| ZmMLO9TM Helix 2] [Intervening Region 2 |
| HVMLO1YVDYCPEGKVA |
| HVMLO1YVDYCPEGKVAZMMLO1KYVDYCPEGKVAZMMLO1 |
| ZMMLOZRVAEEGAKICNKKGDVP |
| ZmMLO7RVAEEGAKICNKKGDVP ZmMLO5LLQEGTAGAEQCQKKGKVP ZmMLO8 GRIGRRHSPRRNLKTSYHNHEGCREGYES ZmMLO9 |
| |
| HVMLO1LMSTGSLHQLHVFIFVLAVFHVTYSVITIALSRLKMRTWKKWETETTSLEYQFANDPAR-ZMMLO1 |
| ZMMLO2 LVSADGMHQLHIF VFFLAVFHVSYSAITMALGRAKIRAVKEVEKEAAGQDYEFSHDPTR- |
| ZMMLOZ LLSLEALHQLHIFIFVLGLVHVVFCATTISFSGAKMRKWKHWETEIHREVHEKLQQEKNE |
| ZMMLOS |
| |
| HMLO1FRFTHQTSFVKRHLGLSSTPGIRWVVAFFRQFFRSVTKVDYLTLRAGF |
| HVMLO1FRFTHQTSFVKRHLGLSSTPGIRWVVAFFRQFFRSVTKVDYLTLRAGFZMMLO1FRLTHQTSFVRQHAS-CWSKSTITLYFVSFFRQFFRSVRKTDYFTLRHGFZMMLO6FRFTHETSFVRQHMN-VLNKFPASFYISNFFRQFFRSVRQADYCALRHSF |
| ZMMLOZ GQGSSLSIVVLHREHQDEFVHKRTKGFWMKLAVASWITAFLKQFQDSVSKSDYEALRSAF |
| ZMMLOSVHHHEFIKKRFKGIGKDSIILSVLHSFGKQFYRSVSKSDYTTMRLGF ZMMLO8ATRRQPALTKSYSFRSVSQNVVVMVLVCFIAQFGQSVVRADYLILRKGF |
| ZmMLO4KVMRRQSTFVFNNASHPWSKNKILIWMLCFLRQFKGSIIRSDYLALRLGF |
| TO FIG 18 FIG 4A |

2/5 FROM FIG. 1A.

```
HVMLO1 INAHLSQNSKFDFHKYIKRSMEDDFKVVVGISLPLVGVAILTLFLDINGVGTLIVISFIPZMMLO2 ISAHLSPGTRFNFRKYIKRSLEDDFKTVVGISPPLVASALAVMLFNVHGVHNLFVFSAIP
ZMMLO6 VNVHLAPGSKFDFDKYIDRSLEDDFKVIVGISPPLVASALIFLFLNVNGVHTMLVISIMP
ZMMLOZ VVEHYPEKPDIDFHKYMTRAVEYEFKRVVGISWYLWLFVILFLLLNINGWHTYFWLAFLP
ZMMLO9 IMTHNLPPT-YDFHNYMIRSMEEEFEKIVGVSGLLWGFVVAFMLFNVDGSNLYFVIAILP
ZMMLO4 MTYHKLPHS-YDFHKYMVRSMEDDYNGTIGISVPLVAYAIVCILINVHGINIYFVLSFVP
                 ---Intervening Region 3--] [----TM Helix 4---] [IR 4] [-----TM
HVMLO1LVILLCVGTKLEMIIMEMALEIQDRAS--VIKGAPVVEPSNKFFVFHRPDVVLFFIHLTLZMMLO1-----EIQDKAT--VIKGAPVVEPSDRFFVFNRPGVVLFLIHLTLZMMLO2LVVILAVGTKLQAIIAMMAIEIAERHT--VIQGMPVVKLSDDHFVFGKPRLVLHLIHFAS
ZMMLO6 VVIILSVGTKLQGIICRMAIDITERHA--VIQGIPMVQVSDSYFVFARPTFVLFLIHFTL
ZMMLO7LFLLLIVGAKLEGIITRLAQEAAISLSN-NTEEVPKIKPCKDHFVFHKPELVLHLIHFIL
                                                                                                           -IHFIL
ZmML05
ZMMLOBLILLLAIGTKLEHVIAQLAHDVAEKHT--AVEGDVIVKPSDEHFVFGKPRVILYLİHFİL
ZMMLO9 VTLVLLVGAKLQHVIATLTAEGAKMST-----YGPRIQPRDDLFVFKKPEFLLVLİHFVL
ZMMLO4 VELVLLYGTELQHYIAQLALEVAEATA--PY-VGSQLKLRDDLFWFGKPRYLWYLIQFIS
                Helix 5] [----Intervening Region 5---
HVMLO1FQNAFQMAHFVVTVATPGLKKCYHTQIGLSIMKVVVGLALQFLCSYMTFPLYALVTQMGSZMMLO1FQNAFQMAHFVVTLLTPDLKKCYHERLGLSIMKVAVGLVLQVLCSYITFPLYALVTQMGSZMMLO2FQNAFEITYFFVIVYEFGLRSCFHDNFEFIIARVCLGATVQFMCSYITLPLAYALVSQMGSZMMLO6FQNGFQIIYFLVILYEYGMDSCFNDSEEFVFARLCLGVVVQVLCSYVTLPLYALVSQMGS
HMLO1 NMKRS IF DEDTSKALTNYRNTAKEKKKYR--DTDMLMAQMIGDATPSRGSS-PMPSRGSS ZMMLO1 HMKKT IF EEDTAKAVMKYRKTAKDKYRORE-AAGF LDVLTSADTTPSHSRA-TSPSRGNSZMM LO2 EMKRT IF DEDTAKALKKYHKAVYKKKHHK------DSSHNSSETPSTDTTGPAGEAGEV
 ZMMLOG TMKOSIFDEOTSKALKNVRAGAKKKAPTG-
                                                                   ----GSKHGGGGSPTAGGS-PTKADGDA
Zmml oz qiklhgfgsrvhesvhgviglrkkpfsfvkipggdpnadsgreadvtrrvakersgssrs zmml os ffkkeifdehvqqsllgvaqkakkrkalrnngngsngaaag-sshpsatarlelmrava zmml os cykkeifnehvqqgvlgvaqkvkmkkglk--g-----AAS--ASKDESITNADSAGPSVK zmml os kykaaliprriretihgvgkatrkkrrrr--RGDDSTVRTETSTVCSLTDDDEDFEDDDD zmml o4 kfkkslvsenvreslhsvckrvkdrsrhn--plfsrngtlttrsvcsldttyetdhetnt
HVMLO1 -----PVHLLHKGM------GRSDDPQSAPTSPRT-----QQEARDMYPVVVAHZMMLO1 ------GRELGDMYPVADQHZMMLO2 QRLHEVPVRHLHRYKTI-----AHVGGVRSPLSDPDYSDTDDTEPLSLQTRHLIPPAKQR
 ZmML06 -
                --EDVEIVGNTG-----
 ZmMLO8-----IEMAKAG-----
 ZMML 09 HHHHGPSYDTPRAGGRPPYLKIETHRQSGSGHDGPRPGGTPCFHPSGSGSGHAMLLRQAS
ZMML 04 vctlsrtasatslddql-----tvytvddepsciekdv----------
                                                     --C-Terminus
```


TO FIG. 1C.


FIG. 1B.

3/5

| HVML01PVHRLNPNDRRRSASSSALEADIPSADFSFSQGZMML01RLHRLDP-ERMRPASSTAVNIDIADADFSFSMRZMML02SLDTERAEVRVNVVETAAAPSDVLQDSFSFPRLLPPRHVPDK-ZMML06 | 224 565 515 | |
|---|-------------------|----------|
| ZmMLO7ZmMLO5ZmMLO8ZmMLO8ZmMLO9VSAPSSPSYRGGNNVTRSASMPGIAALRTTGSGTPTRVSHEEPT | 499 149 | 00 00 |
| 7MI O 1 | 492 469 509 | 00 00 |
| ZmMLO4 | JU 7 | uu |
| FIC 4C | | |







SEQUENCE LISTING

```
<110> Briggs, Steven
<120> Manipulation of Mlo Genes to Enhance Disease Resistance
      in Plants
<130> 5718-42035718/158714
<140>
<141>
<160> 20
<170> PatentIn Ver. 2.0
<210> 1
<211> 845
<212> DNA
<213> Zea mays
<220>
<223> Mlo1
<400> 1
aggagataca ggacaaggcg acggtcatca agggggcgcc tgtggtggag ccaagtgaca 60
qqttcttctq qtttaaccqc cctqqctqqq tcctcttcct catccacctc acqctcttcc 120
agaacgcctt ccagatggcg catttcgttt ggacactgct caccccagac ctgaagaaat 180
gctaccacga gaggctgggc ctgagcatca tgaaagttgc ggtggggctg gttctccagg 240
tectetgeag ctacateace treeegetet aegegetegt caegeagatg gggtegeaca 300
tgaagaagac catcttcgag gagcagacgg ccaaggcggt gatgaagtgg cgcaagacgg 360
ccaaggataa ggtgcggcag cgggaggcgg caggctteet cgaegtgetg acgagegeeg 420
acaccacgc gagccacagc cgcgcgacgt cgccgagccg gggcaactcg coggtgcacc 480
tgctccacaa gtacaggggc aggtcggagg aaccgcagag cgggccggcg tcgccggggc 540
gggagctcgg ggacatgtac ccggtggctg accagcatcg cctgcacagg ctggaccccg 600
 aqaqqatqaq gecegeeteg tecacegeeg teaacattga categetgat geegattttt 660
 cttttagcat geggtgacct gaccttgaac gaattetgtg teettactet tgtataggga 720
 atcataaaat agaatacgta ataaactagt atctccctct tcaaaaaaaa aaaaaaaaa 840
                                                                845
 aaaaa
 <210> 2
 <211> 224
 <212> PRT
 <213> Zea mays
 <220>
 <223> Mlol
```

| <400 | | • | | | | | | | | | | | | | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|-----------|------------|------------|------------|------------|------------|
| Glu 1 | Ile | Gln | Asp | Lys 5 | Ala | Thr | Val | Ile | Lys 10 | Gly | Ala | Pro | Val | Val 15 | Glu |
| Pro | Ser | Asp | Arg 20 | Phe | Phe | Trp | Phe | Asn 25 | Arg | Pro | Gly | Trp | Val 30 | Leu | Phe |
| Leu | Ile | His 35 | Leu | Thr | Leu | Phe | Gln 40 | Asn | Ala | Phe | Gln | Met 45 | Ala | His | Phe |
| Val | Trp | | Leu | Leu | Thr | Pro 55 | Asp | Leu | Lys | Lys | Cys 60 | Tyr | His | Gļu | Arg |
| Leu 65 | Gly , | Leu | Ser | Ile | Met 70 | Lys | Val | Ala | Val | Gly 75 | Leu | Val | Leu | Gln | Val 80 |
| Leu | Cys | Ser | Tyr | 11e 85 | Thr | Phe | Pro | Leu | Туг 90 | Ala | Leu | Val | Thr | Gln 95 | Met |
| Gly | Ser | His | Met 100 | Lys | Lys | Thr | Ile | Phe 105 | Glu | Glu : | Gln | Thr | Ala 110 | Lys | Ala |
| Val | Met | Lys 115 | Trp | Arg | Lys | Thr | Ala 120 | Lys | Asp | Lys | . Val | Arg 125 | Gln | Arg | Glu |
| Ala | Ala 130 | | Phe | Leu | Asp | Val 135 | Leu | Thr | Ser | Ala | Asp 140 | | Thr | Pro | Ser |
| His 145 | | Arg | Ala | Thr | Ser 150 | | Ser | Arg | Gly | 155 | | Pro | Val | His | Leu 160 |
| Leu | His | Lys | Туг | Arg 165 | | Arg | Ser | Glu | 170 | | Gln | Ser | Gly | Pro 175 | |
| Ser | Pro | Gly | / Arg | | Leu | Gly | Asp | Met 185 | | Pro | Val | Ala | 190 | | . His |
| Arg | , Leu | 195 | | , Leu | Asp | Pro | 200 | | , Met | . Arc | Pro | 205 | s Ser | Ser | Thr |
| Ala | Val 210 | | ıle | e Asp | Ile | 215 | | Ala | a Asp | Phe | 220 | | e Ser | . Met | Arg |

<210> 3

```
<211> 2030
<212> DNA
<213> Zea mays
<220>
<223> Mlo2
<400> 3 .
gcggcaagca attgtctcat ctgctccact ccatctccat ttaacgcact ctccactcct 60
tcgcggcggg ggtttaggcg cacggcggca ggccaattaa cgccgctgcg gcgagcaccg 120
ggggggaaat gggcggcgac ggcacgaggg cgctggacca gacgccgacg tgggccgtgg 180
ccgccgtctg cgctgtcatc gtcgcggcgt ccatactcct cgagggcttc ctccaccacc 240
tcggtcagtt gctcaacaag aagcggaaga aggcgctgtt tgacgctctg gagaaggtta 300
aatcqqaqct gatgactctg gggttcatat cgctgctgct gaccgtgacg ggaaggtaca 360
togogogoat otgoatocog gagggagoog caaacaccat getgecetge egectgteeg 420
gtcactcggt ggcggaagag cccaagggcc atggccgacg gcacctatct gaagatccaa 480
ccaacetttt tteetgeege aaaggeatgg tgregertgt tteageegae ggeatgeate 540
agetgeacat titegigtte tietiggeeg tettecatgt tacetteagt tietteacaa 600
tgtccttggg tagagcaaag actcgtatat ggaaggtgtg ggaaaaggaa acttgctccc 660
ctcagtataa ttatttaaat gaccceteaa agtteagget taegeaceaa acatettttg 720
tgaggcaaca tgcaagttgt tggagcaaaa gcacaatcac gctctatttt gtgagcttct 780
ttaggcagtt cttcagatcc gtccgtaaga cagactactt tactttgcga catggattca 840
tttcagctca tttatctccg gggactaggt tcaattttcg aaagtacatt aaaaggtcct 900
tggaggatga tttcaagaca gttgttggca ttagtccacc actatgggct tctgctttgg 960
ctgtcatgct gttcaatgtt catggatggc acaacttatt ctggttctct gcaattcccc 1020
ttgtagttat tctagcagtt ggaacaaagc tgcaggctat aattgctatg atggctattg 1080
aaattgcaga gaggcataca gttatccaag gcatgccggt ggtaaaacta agtgatgatc 1140
atttctggtt cgggaageet cgtttggtte tecaceteat teatttegea teatttcaga 1200
acgcatttga aattacatat ttcttttgga tctggtacga atttggcctg aggtcctgct 1260
tccatgacaa ctttgagttt atcattgcaa gagtctgcct tggggctatc gtccagttta 1320
 tgtgcagcta carcaccett ceactetatg ceettgttte teagatgggt teagaaatga 1380
 agcgaacaat tttcgacgag cagacagcga aggccctgaa gaaatggcac aaggccgtgg 1440
 tgaagaagaa acaccacaag gatteeteac acaattette egagaeteet agcaetgaca 1500
 caacaggacc tgcaggggaa gcgggtgagt ggcagcggct gcacgaggtg ccggtccggc 1560
 acctccaccg gtacaagacc atcgcgcacg tcggcggcgt gaggagcccg ttgtcggacc 1620
 cggactacag cgacacggac gacaccgagc cgctgtcgtt gcagactagg cacctgatac 1680
 cgccggcgaa gcagcggagc ctcgacaccg agcgcgcgga ggtgcgcgtg aacgtcgtag 1740
 agacagegge ggegeeaage gaegteetee aagacagett etegtteeea aggetgette 1800
 ctcctcgcca tgtgccggac aagtaaagtg gccagcagtc tgcttagtac tacagactgt 1860
 cctatataga gatagtagaa tagtagtttc aagttataag tcgatttggc tagttataca 1920
 acttttgtta tttatttaga taaaggctat gtctatatag caaaagttgt aaaactagaa 1980
                                                                  2030
 <210> 4
 <211> 565
 <212> PRT
```

<213> Zea mays

<220> <223> Mlo2

<400> 4

Met Gly Gly Asp Gly Thr Arg Ala Leu Asp Gln Thr Pro Thr Trp Ala
1 5 10 15

Val Ala Ala Val Cys Ala Val Ile Val Ala Ala Ser Ile Leu Leu Glu 20 25 30

Gly Phe Leu His His Leu Gly Gln Leu Leu Asn Lys Lys Arg Lys Lys 35 40 45

Ala Leu Phe Asp Ala Leu Glu Lys Val Lys Ser Glu Leu Met Thr Leu 50 55 60

Gly Phe Ile Ser Leu Leu Thr Val Thr Gly Arg Tyr Ile Ala Arg
65 70 75 80

Ile Cys Ile Pro Glu Gly Ala Ala Asn Thr Met Leu Pro Cys Arg Leu 85 90 95

Ser Gly His Ser Val Ala Glu Glu Pro Lys Gly His Gly Arg Arg His 100 105 110

Leu Ser Glu Asp Pro Thr Asn Leu Phe Ser Cys Arg Lys Gly Met Val 115 120 125

Ser Leu Val Ser Ala Asp Gly Met His Gln Leu His Ile Phe Val Phe 130 135 140

Phe Leu Ala Val Phe His Val Thr Phe Ser Phe Phe Thr Met Ser Leu 145 150 155 160

Gly Arg Ala Lys Thr Arg Ile Trp Lys Val Trp Glu Lys Glu Thr Cys 165 170 175

Ser Pro Gln Tyr Asn Tyr Leu Asn Asp Pro Ser Lys Phe Arg Leu Thr
180 185 190

His Gln Thr Ser Phe Val Arg Gln His Ala Ser Cys Trp Ser Lys Ser 195 200 205

Thr Ile Thr Leu Tyr Phe Val Ser Phe Phe Arg Gln Phe Phe Arg Ser 210 215 220

Val Arg Lys Thr Asp Tyr Phe Thr Leu Arg His Gly Phe Ile Ser Ala

| ,225 | | | | | 230 | | | | | 235 | | | | | 240 |
|------------|------------|------------|------------|---------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| His | Leu | Ser | Pro | Gly 2 4 5 | Thr | Arg | Phe | Asn | Phe 250 | Arg | Lys | Tyr | Ile | Lys 255 | Arg |
| Ser | Leu | Glu | Asp 260 | Asp | Phe | Lys | Thr | Val 265 | Val | Gly | Ile | Ser | Pro 270 | Pro | Leu |
| Trp | Ala | Ser 275 | Ala | Leu | Ala | Val | Met 280 | Leu | Phe | Asn | Val | His 285 | Gly | Trp | His |
| Asn` | Leu 290 | Phe | Trp | Phe | Ser | Ala 295 | Ile | Pro | Leu | Val | Val 300 | Île | Leu | Ala | Val |
| Gly 305 | Thr | Lys | Leu | Gln | Ala 310 | Ile | Ile | Ala | Met | Met 315 | Ala | Ile | Glu | Ile | Ala 320 |
| Glu | Aṛg | His | Thr | Val 325 | Ile | Gln | Gly | Met | Pro 330 | | Val | Lys | Leu | Ser 335 | Asp |
| Asp | His | Phe | Trp 340 | | Gly ~ | Lys | Pro | Arg 345 | Leu | Val | Leu | His | Leu 350 | Ile | His |
| Phe | Ala | Ser 355 | | Glņ | Asn | Ala | Phe 360 | | Ile | Thr | Tyr | Phe 365 | Phe | Trp | Ίle |
| Trp | Tyr 370 | Glu | Phe | Gly | Leu | Arg 375 | | Cys | Phe | His | Asp 380 | Asn | Phe | .Glu | Phe |
| Ile 385 | Ile | Aļa | Arg | Val | Cys 390 | | Gly | Ala | Ile | Val 395 | | Phe | Met | Cys | Ser 400 |
| Tyr | Ile | Thr | Leu | Pro 405 | | Tyr | Ala | Leu | Val 410 | | Gln | Met | Gly | Ser 415 | |
| Met | Lys | Arg | 420 | | Phe | Asp | Glu | 425 | | Ala | Lys | Ala | 430 | | Lys |
| Trp | His | Lys 435 | | val | . Val | Lys | | Lys | | : His | Lys | Asp 445 | Ser | Ser | His |
| Asr | 450 | | Glu | Thi | Pro | Ser 455 | | Asp | Thr | Thr | Gly 460 | | Ala | Gly | , Glu |
| Ala 465 | . – | / Glu | ı Tr | Gl: | Arg 470 | | ı His | s Glu | ı Val | 1 Pro | | . Arq | g His | Let | 480 |
| Arc | יעד נ | Lvs | s Thi | r Ile | a Ala | a His | s Vai | l Gly | y Gly | y Val | L Arc | , Sei | Pro | Le | ı Ser |

485 490 495

Asp Pro Asp Tyr Ser Asp Thr Asp Asp Thr Glu Pro Leu Ser Leu Gln 500 505 510

Thr Arg His Leu Ile Pro Pro Ala Lys Gln Arg Ser Leu Asp Thr Glu 515 520 525

Arg Ala Glu Val Arg Val Asn Val Val Glu Thr Ala Ala Ala Pro Ser 530 535 540

Asp Val Leu Gln Asp Ser Phe Ser Phe Pro Arg Leu Leu Pro Pro Arg 545 550 555 . 560

His Val Pro Asp Lys 565

<210> 5

<211> 1841

<212> DNA

<213>. Zea mays

<220> .

<223> Mlo4

<400> 5

agatatcagg gcagctggaa ctgaaggtgg cgggagccga gtgatccggc ggtgagctga 60 gcggggcggg atggcggcgg agcaggggcg gtcgctggcg gagacgccca cctggtccgt 120 ggcaaccgtc accacgctca tggtcgctgc ctgcttcctc gtcgagcgct ccctctcgcg 180 cttcgccaag tggctgcgca agaccaagcg gaaggccatg ctcgccgcgc tcgagaagat 240 ccgcgaagag ctgatgctgc tcggagtcat ctcgctgctg ctcagccaga cggcgcgctt 300 catateggag atetgegtge egteeteget etteaceage egettetaea tetgeteega 360 gagegactae caggacetge tgegeaacae ggaegecaae cagaeggege tegacaagaa 420 catgttcggt ggccaacggc tgcacgtctg tggcgagggc catgaacctt ttgtttcgta 480 cgagggcctt gagcagctgc accggtttct cttcatcctt ggtatcactc atgtgttgta 540 cagttttgta acagtggttc tgtccatgat caagatctat agctggagga agtgggaaac 600 cttagcaggt ccaattgctg ctgaggaatt gaaagctagg agaaccaagg tgatgagaag 660 gcagtcaacc tttgttttta acaatgcttc tcatccatgg agcaaaaata aaatacttat 720 ttggatgctt tgctttttgc gtcaattcaa gggctccata ataaggtcag actatttggc 780 actgaggttg ggctttgtca catatcacaa gctaccacat tcatatgact tccataaata 840 catggtacgg agcatggaag atgattacaa tgggactatt ggtatcagtt ggccactttg 900 ggcatatgcg attgtctgca tattaatcaa tgttcatggt atcaatatat atttctggtt 960 gteetttgtt eetgttatte tggtgettet agtgggtaet gaactteage aegteattge 1020 tcagttggct ttggaagtcg ctgaggcaac agcgccttat gttggctcac aacttaaact 1080 gcgtgatgat ctattttggt ttggaaagcc tcgggtactc tggtggctta tacagttcat 1140 ttcatttcag aatgcttttg agctggcaac attcttatgg tctctgtggg aactcagtgc 1200 acaaacatgt ttcatgaagc actactacat ggttgccatt cggttgattt ctgggctcct 1260

agttcagttt tggtgcagct acagcacact gccgctgaat gtgattattt ctcagatggg 1320 ttccaagttc aagaaatcac tggtctcgga gaacgtgagg gagtcgctgc acagctggtg 1380 caagagggtt aaggacagga gccgacacaa tccgctcttc tcgcggaacg ggaccctcac 1440 gaccagatcc gtgtgctcc tagacacaca ctacgagacg gatcacgaga cgaacacggt 1500 gtgcacgctg tcgaggacgg cgtcggcgac gtcgctggac gaccagttga ccgtggtcac 1560 cgtcgatgac gagccgtcct gcattgagaa ggatgtctga cgcagttga ccgtggtcac 1620 aactacatac tgcaccgacc tgtgtgttag gaggtactct aggactgaaa tgaatgtata 1680 tgtgcagtgg ttgcccctat cgtggcagtg accatgtga tatatagaac taaaaaaact 1740 ataatgtctc ttagctgaa gtgagaggct gtacatggaa acaatacaaa actgcatct ttcgagaaaa aaaaaaaaa a

<210> 6

<211> 509

<212> PRT

<213> Zea mays

<220>

<223> Mlo4

<400> 6

Met Ala Ala Glu Gln Gly Arg Ser Leu Ala Glu Thr Pro Thr Trp Ser

1 5 10 15

Val Ala Thr Val Thr Thr Leu Met Val Ala Ala Cys Phe Leu Val Glu 20 25 30

Arg Ser Leu Ser Arg Phe Ala Lys Trp Leu Arg Lys Thr Lys Arg Lys 35 40 . 45

Ala Met Leu Ala Ala Leu Glu Lys Ile Arg Glu Glu Leu Met Leu Leu 50 55 60

Gly Val Ile Ser Leu Leu Ser Gln Thr Ala Arg Phe Ile Ser Glu
65 70 75 80

Ile Cys Val Pro Ser Ser Leu Phe Thr Ser Arg Phe Tyr Ile Cys Ser

Glu Ser Asp Tyr Gln Asp Leu Leu Arg Asn Thr Asp Ala Asn Gln Thr 100 105 110

Ala Leu Asp Lys Asn Met Phe Gly Gly Gln Arg Leu His Val Cys Gly
115 120 125

Glu Gly His Glu Pro Phe Val Ser Tyr Glu Gly Leu Glu Gln Leu His 130 135 140

Arg Phe Leu Phe Ile Leu Gly Ile Thr His Val Leu Tyr Ser Phe Val

| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Thr | Val | Val | Leu | Ser 165 | Met | Ile | Lys | Ile | Tyr 170 | Ser | Trp | Arg | | Trp 175 | Glu |
| Thr | Leu | Ala | Gly 180 | Pro | Ile | Ala | Ala | Glu 185 | Glu | Leu | Lys | Ala | Arg 190 | Arg | Thr |
| Lys | Val | Met 195 | Arg | Arg | Gln | Ser | Thr 200 | Phe | Val | Phe | Asn | Asn 205 | Ala | Ser | His |
| Pro | Trp 210 | Ser | Lys | Asn | Lys | Ile 215 | Leu | Ile | Trp | Met | Leu 220 | Cys | Phe | Leu | Arg |
| Gln 225 | `Phe | Lys | Gly | Ser | Ile 230 | Ile | Arg | Ser | Asp | Tyr 235 | Leu | Ala | Leu | Arg | Leu 240 |
| Gly | Phe | Val | Thr | Tyr 245 | His | Lys | Leu | Pro | His 250 | Ser | Tyr | Asp | Phe | His 255 | Lys |
| туг | Met | Val | Arg 260 | Ser | Met | Glu | Asp | Asp 265 | Tyr | Asn | Gly | Thr | 11e 270 | Gly | Ile |
| Ser | Trp | Pro 275 | Leu | Trp | Ala | Tyr | Ala 280 | Ile | Val | Cys | Île | Leu 285 | Ile | Asn | Val |
| His | Gly 290 | | Asn | Ile | Tyr | Phe 295 | Trp | Leu | Ser | Phe | Val 300 | Pro | Val | Ile | Leu |
| Val 305 | | Leu | Val | Gly | Thr 310 | Glu | Leu | Gln | His | Val 315 | | Ala | Gln | Leu | Ala 320 |
| Leu | Glu | Val | Ala | Glu 325 | | Thr | Ala | Pro | Туг 330 | | Gly | Ser | Gln | Leu 335 | Lys |
| Leu | Arg | Asp | 340 | | Phe | Trp | Phe | Gly 345 | | Pro | Ärg | Val | Leu 350 | Trp | Trp |
| Leu | Ile | Gln 355 | | Ile | Ser | Phe | Gln 360 | | Ala | Phe | Glu | Leu 365 | | Thr | Phe |
| Leu | 370 | | : Leu | Trp | Glu | Leu 375 | | Ala | Gln | Thr | Cys | | Met | Ļys | His |
| Туг 385 | _ | . Met | : Val | . Ala | 390 | | Leu | Ile | e Ser | Gly 395 | | . Leu | ı Val | Gln | Phe 400 |
| Trp | Cys | Lev | туг | Sex | Thr | Leu | Pro | Leu | a Asr | val | . Ile | · Ile | Ser | Gln | Met |

415 410 405 Gly Ser Lys Phe Lys Lys Ser Leu Val Ser Glu Asn Val Arg Glu Ser 430 420 425 Leu His Ser Trp Cys Lys Arg Val Lys Asp Arg Ser Arg His Asn Pro 440 435 Leu Phe Ser Arg Asn Gly Thr Leu Thr Thr Arg Ser Val Cys Ser Leu 455 Asp Thr Thr Tyr Glu Thr Asp His Glu Thr Asn Thr Val Cys Thr Leu 475 480 470 Ser Arg Thr Ala Ser Ala Thr Ser Leu Asp Asp Gln Leu Thr Val Val 495 490 485 Thr Val Asp Asp Glu Pro Ser Cys Ile Glu Lys Asp Val 505 500 <210> 7 <211> 673 <212> DNA <213> Zea mays <220> <223> Mlo5 <400> 7 tgatccactt catcctcttc cagaacgcgt ttgagatcgc attcttcttc tggattctga 60 ctacctacgg tttcaactcc tgcatcatgg accacgtccc cttcattgtg ccgaggctcg 120 ttgtcggggc catcatccag ctcctctgta gctacagcac cctgcctctg tacgcgattg 180 tcacgcagat ggggactttc ttcaagaagg agatcttcga tgagcacgtg cagcagagcc 240 ttctqqqctq qqcqcaqaaq qccaaqaaqa qqaaaqcqct caqqaacaat qqcaatqqca 300 gcaatggcgc cgcggccggg tcgtcacatc catctgcgac tgcgaggctc gaactgatga 360 gacgagctgt cgctcttgaa gaaggcagtg ccggtggcaa cgggagtgag gctagtgcgg 420 ccgagctaca cgacacgggc ccgaagctct gaacgctgta gaaaacgccc ggcagagcgt 480 cagaagatgc agtgtttctg tacgcgagcc atatgtcact atgtcgtgtg gctgtttagc 540 caggtggtgt agtgtgatac tgcgtatcat gatttgtatg cttttctgga ttgagcttga 600 agcgtgttat ggagtgggga gctttgtgta gtgttgtgct caaaaaaaaa aaaaaaaaa 660 673 aaaaaaaaa aaa <210> 8 <211> 149

<212> PRT <213> Zea mays

<220>

<223> Mlo5

<400> 8

Ile His Phe Ile Leu Phe Gln Asn Ala Phe Glu Ile Ala Phe Phe 1 5 10 15

Trp Ile Leu Thr Thr Tyr Gly Phe Asn Ser Cys Ile Met Asp His Val 20 25 30

Pro Phe Ile Val Pro Arg Leu Val Val Gly Ala Ile Ile Gln Leu Leu 35 40 45

Cys Ser Tyr Ser Thr Leu Pro Leu Tyr Ala Ile Val Thr Gln Met Gly
50 55 60

Thr Phe Phe Lys Lys Glu Ile Phe Asp Glu His Val Gln Gln Ser Leu 65 70 75 80

Leu Gly Trp Ala Gln Lys Ala Lys Lys Arg Lys Ala Leu Arg Asn Asn 85 90 95

Gly Asn Gly Ser Asn Gly Ala Ala Ala Gly Ser Ser His Pro Ser Ala 100 105 110

Thr Ala Arg Leu Glu Leu Met Arg Arg Ala Val Ala Leu Glu Glu Gly 115 120 125

Ser Ala Gly Gly Asn Gly Ser Glu Ala Ser Ala Ala Glu Leu His Asp 130 135 140

Thr Gly Pro Lys Leu 145

<210> 9

<211> 1815

<212> DNA

<213> Zea mays

<220>

<223> Mlo6

<400> 9

aagcgatcga tagaataaat taaaggcgcg ggggcaacaa caagaatggg gggcggtggc 60 ggtggcggca actcgcggga gcttgaccag acgccgacat gggcggtggc gtcggtgtc 120 ggcgtgatcg tgctcatctc catcctgctg gagaaggggc tccaccacgt gggcgagttc 180 ttctcccacc gcaagaagaa ggccatggtg gaggccctgg agaaggtgaa ggcggagctc 240

```
atggtgctgg gcttcatctc gctcctcctc gtgttcggcc agaactacat catcaaggtc 300
tgcatcagca accaegeege caacaecatg eteceetgea agetegagge egeegeegte 360
gagggcaagg acggccacgg caaggaggcc gccgccgtgg tcgctggcaa gaagaaggtc 420
gccgtcgccg tccctggaaa gaagaagaag aaggccgccg ccgccgccga ccatcttggc 480
ggtgtggtgg actggccgcc gccctactac gcgcacaacg ccaggatgct ggcggaggcg 540
agcatggcga ccaagtgccc cgaggggaaa gtgccgctca tctccatcaa cgccctgcac 600
cagetycaca tetteatett etteetegee gtettecaeg teteetaeag egeaateaee 660
atggcgctcg gcagggccaa gatacgtgca tggaaagagt gggagaaaga agctgcagga 720
caaqactacg agtteteaca tgaceegaeg eggtteaggt teaceeacga gaetteette 780
gtgaggcagc atatgaatgt gctgaacaag ttcccagcat cattctacat cagcaacttc 840
ttccggcagt tcttcaggtc cgtgaggcag gcagactact gcgcgctgcg ccacagcttt 900
gtcaacgtcc atctggcccc tggcagcaag tttgatttcc agaagtacat caagcggtct 960
ctggaggatg acttcaaggt gatcgtgggg atcagtcctc ctctgtgggc ttctgctctc 1020
atcttcctct tcctcaacgt caatggatgg cacaccatgc tctggatctc catcatgccg 1080
gtggtgatca tcctgtcggt ggggacgaag ctgcagggca tcatctgccg catggcgatc 1140
qacatcacqq agcgccacgc cgtcatccag ggcatcccga tggtgcaagt cagcgactcc 1200
tacttetggt tegeaegece eacettegtg etetteetea teeaetteae eetetteeag 1260
aatggcttcc agatcatcta cttcctctgg attctgtatg agtacggcat ggactcgtgc 1320
ttcaacgact ccgaagagtt cgtctttgca cgactctgcc ttggcgtggt tgtccaggtg 1380
ctgtgcagct acgtgacgct cccgctgtac gcgctcgtct cccaaatggg ctccaccatg 1440
aagcagtcca tottogacga gcagacotoo aaggegotoa agaactggog cgccggogoo 1500
aagaagaagg ctcccaccgg cggctccaag cacggcggtg gtggctcccc caccgccggc 1560
ggcagcccca ccaaggccga cggcgacgcg tagagaggaa cacgctaact ttaatttctg 1620
tgtgcttaat tgcctaggct cgttaagtca gaacatgcat gcatgtaaca ccactgctgg 1680
ttttcatata gtgtcgacag atggtcaacg tactttttgc gatcccactt gtatttttt 1740
1815
aaaaaaaaa aaaaa
<210>.10
<211> 515
<212> PRT
<213> Zea mays
```

<220>

<223> Mlo6

<400> 10

Met Gly Gly Gly Gly Gly Gly Asn Ser Arg Glu Leu Asp Gln Thr
. 1 5 10 15

Pro Thr Trp Ala Val Ala Ser Val Cys Gly Val Ile Val Leu Ile Ser
20 25 30

Ile Leu Leu Glu Lys Gly Leu His His Val Gly Glu Phe Phe Ser His 35 40 45

Arg Lys Lys Ala Met Val Glu Ala Leu Glu Lys Val Lys Ala Glu
50 55 60

| Leu 65 | Met | Val | Leu | Gly | Phe 70 | Ile | Ser | Leu | Leu | Leu 75 | Val | Phe | Gly | Gln | Asn 80 |
|------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-------------|------------|------------|------------|------------|------------|
| Tyr | Ile | Ile | Lys | Val 85 | Cys | Ile | Ser | Așn | His 90 | Ala | Ala | Asn | Thr | Met 95 | Leu |
| Pro | Cys | Lys | Leu 100 | Glu | Ala | Ala | Ala | Val 105 | Glu | Gly | ·Lys | Asp | Gly 110 | His | Gly |
| Lys | Glu | Ala 115 | Ala | Ala | Val | Val | Ala 120 | Gly | Lys | Lys | Lys | Val 125 | Ala | Val | Ala |
| Val _, | Pro 130 | Gly | Lys | Lys | Lys | Lys 135 | Lys | Ala | Ala | Ala | Ala 140 | Ala | Asp. | His | Leu |
| Gly 145 | Gly | Val | Val | Asp | Trp 150 | Pro | Pro | Pro | Туr | Tyr 155 | Ala | His | Asn | Ala | Arg 160 |
| Met | Leu | Ala | Glu | Ala 165 | Ser | Met | Ala | Thr | Lys 170 | Cys | Pro | Glu | | Lys 175 | Val |
| Pro | Leu | Ile | Şer 180 | Ile | Asn | Ala | Leu | His 185 | ·Gln | Leu | His | Ile | Phe 190 | ile | Phe |
| Phe | Leu | Ala 195 | Val | Phe | His | Val | Ser 200 | Tyr | Ser | Ala | Ile | Thr 205 | Met | Ala | Leu |
| Gly | Arg 210 | Ala | Lys | Ile | Arg | Ala 215 | Trp | Lys | Glu | Trp | Glu 220 | Lys | Glu | Ala | Ala |
| Gly 225 | Gln | Asp | Туr | Glu | Phe 230 | Ser | His | Asp | Pro | Thr 235 | Arg | Phe | Arg | Phe | Thr 240 |
| His | Glu | Thr | Ser | Phe 245 | Val | Arg | Gln | His | Met 250 | Asn | Val | Leu | Asn | Lys 255 | Phe |
| Pro | Ala | Ser | Phe 260 | Туг | Ile | Ser | Asn | Phe 265 | Phe | Arg | Gln | Phe | Phe 270 | Arg | Ser |
| Val | Arg | Gln 275 | Ala | Asp | Tyr | Cys | Ala 280 | Leu | Arg | His | Ser | Phe 285 | Val | Asn | Val |
| His | Leu 290 | Ala | Pro | Gly | Ser | Lys 295 | Phe | Asp | Phe | Gln | Lys 300 | Tyr | Ile | Lys | Arg |
| Ser 305 | Leu | Glu | Asp | Asp | Phe 310 | | Val | Ile | Val | Gly. 315 | Ile | Ser | Pro | Pro | Leu 320 |

Trp Ala Ser Ala Leu Ile Phe Leu Phe Leu Asn Val Asn Gly Trp His
325 330 335

Thr Met Leu Trp Ile Ser Ile Met Pro Val Val Ile Ile Leu Ser Val 340 345 350

Gly Thr Lys Leu Gln Gly Ile Ile Cys Arg Met Ala Ile Asp Ile Thr 355 360 365

Glu Arg His Ala Val Ile Gln Gly Ile Pro Met Val Gln Val Ser Asp 370 375 ~ 380

Ser Tyr Phe Trp Phe Ala Arg Pro Thr Phe Val Leu Phe Leu Ile His 385 390 395 400

Phe Thr Leu Phe Gln Asn Gly Phe Gln Ile Ile Tyr Phe Leu Trp Ile 405 410 415

Leu Tyr Glu Tyr Gly Met Asp Ser Cys Phe Asn Asp Ser Glu Glu Phe
420 425 430

Val Phe Ala Arg Leu Cys Leu Gly Val Val Gln Val Leu Cys Ser 435 440 445

Tyr Val Thr Leu Pro Leu Tyr Ala Leu Val Ser Gln Met Gly Ser Thr 450 455 460

Met Lys Gln Ser Ile Phe Asp Glu Gln Thr Ser Lys Ala Leu Lys Asn 465 470 475 480

Trp Arg Ala Gly Ala Lys Lys Lys Ala Pro Thr Gly Gly Ser Lys His
485 490 495

Gly Gly Gly Ser Pro Thr Ala Gly Gly Ser Pro Thr Lys Ala Asp 500 505 510

Gly Asp Ala 515

<210> 11

<211> 1660

<212> DNA

<213> Zea mays

<220>

<223> Mlo7

```
<400> 11
gctagcagga gccaggtcgc gccgacagca gcagttggaa gaggatccat ggggaaggag 60
gcgacgcttg cgttcacgcc cacctgggtg gtggccatcg tatgcctcgt catcgtctct 120
atotocotog cogotgagog otoactocat tacotoggoa agtatotoga gtgtaagaag 180
cagaaagcgc ttttttcagc tctacagaga ctaaaagaag agctaatgct tctcggattc 240
atttcattcq teetgagtet eteceaaggt tttattgtta geatttgeat teeagaaact 300-
tctactgact tcatgcttcc atgcaataga ggcaactcca gagttgcaga agaaggtgct 360
aaaatttgca acaaaaaggg tgatgttccc ttgctatcac tggaggcatt acatcagctg 420
cacattttca tatttgtact tggtttagtc catgttgtgt tctgcgctac aacaatatca 480
tttagtgggg ccaagatgag aaagtggaag cattgggaaa cagaaattca cagagaagta 540
catgagaagt tacagcaaga aaagaatgaa ggacaagggt catcattgag tattgttgtg 600
ctacatcggg agcaccagga tgaatttgtc cacaagcgga caaagggatt ttggatgaag 660
ctcgctgttg caagctggat aactgcattc ttgaagcaat ttcaagattc agtgagtaaa 720
tcagattatg aagcacttag atcagetttt gtcgtggaac actatcccga gaaaccagat 780
attgatttcc acaaatacat gactcgcgct gttgaatatg agtttaaaag agttgttggt 840
atcagctggt atctgtggct ttttgtaatc ttattcctgc tgctgaatat aaatggatgg 900
cacacatact totggttggc tttcttgcct ctatttctgt tacttattgt tggtgccaaa 960
ctagagcaca ttatcactcg gttggctcaa gaggcagcga tatcattatc aaataataca 1020
gaggaagttc cgaaaataaa gccatgcaag gaccatttct ggtttcacaa gcctgagcta 1080
gtccttcatt tgatccattt catcctgttc cagaattcgt tcgagattag ttttttcttc 1140
tggattctgg tatcagaagg tttcggttcg tgtatgatgg aacggaagcc ttatgtcatt 1200
tccagacttg ttatcggggt gatcatcgaa gtcatctgca gctatatcac gctgccacta 1260
tacgccatcg tgacccatat gaccggacag atcaagctgc atggttttgg ctcccgcgtg 1320
cacgagagtg tecatggetg gateggettg aggaagaaac cettetegtt etggaagatt 1380
cccggcggtg accctaacgc tgattccggc agggaggccg acgtaacccg cagggtggcc 1440
aaggageggt eggggagete gegeageatg eegatggege eggetgaega gategteace 1500
gtogacgacg togoggtggc tgcagctgcc gttggccaag gaccataaaa ttcctagcta 1560
gcaaacacca gcagggaagg caggcaggct gccgaggtac cgtgcgcagc gggttgatgg 1620
gtcggacgct gcggaaaatt cctcgtgtcg ggagcaggct
                                                                   1660
<210> 12
<211> 499
<212> PRT
<213> Zea mays
<220>
<223> Mlo7
<400> 12
Met Gly Lys Glu Ala Thr Leu Ala Phe Thr Pro Thr Trp Val Val Ala
  1
                                      10
Ile Val Cys Leu Val Ile Val Ser Ile Ser Leu Ala Ala Glu Arg Ser
             20
                                                      30
                                 25
Leu His Tyr Leu Gly Lys Tyr Leu Glu Cys Lys Lys Gln Lys Ala Leu
          35
                              40
                                                  45
```

Phe Ser Ala Leu Gln Arg Leu Lys Glu Glu Leu Met Leu Gly Phe 55 Ile Ser Phe Val Leu Ser Leu Ser Gln Gly Phe Ile Val Ser Ile Cys 65 -70 75 Ile Pro Glu Thr Ser Thr Asp Phe Met Leu Pro Cys Asn Arg Gly Asn 90 85 Ser Arg Val Ala Glu Glu Gly Ala Lys Ile Cys Asn Lys Lys Gly Asp 105 100 Val Pro Leu Ser Leu Glu Ala Leu His Gln Leu His Ile Phe Ile 120 Phe Val Leu Gly Leu Val His Val Val Phe Cys Ala Thr Thr Ile Ser 130 135 140 Phe Ser Gly Ala Lys Met Arg Lys Trp Lys His Trp Glu Thr Glu Ile 145 150 155 His Arg Glu Val His Glu Lys Leu Gln Gln Glu Lys Asn Glu Gly Gln 165 170 Gly Ser Ser Leu Ser Ile Val Val Leu His Arg Glu His Gln Asp Glu 185 Phe Val His Lys Arg Thr Lys Gly Phe Trp Met Lys Leu Ala Val Ala 200 Ser Trp Ile Thr Ala Phe Leu Lys Gln Phe Gln Asp Ser Val Ser Lys 210 Ser Asp Tyr Glu Ala Leu Arg Ser Ala Phe Val Val Glu His Tyr Pro 235 230 . Glu Lys Pro Asp Ile Asp Phe His Lys Tyr Met Thr Arg Ala Val Glu 250 Tyr Glu Phe Lys Arg Val Val Gly Ile Ser Trp Tyr Leu Trp Leu Phe 265 Val Ile Leu Phe Leu Leu Leu Asn Ile Asn Gly Trp His Thr Tyr Phe 275 280 Trp Leu Ala Phe Leu Pro Leu Phe Leu Leu Ile Val Gly Ala Lys 290 295 300

Leu Glu His Ile Ile Thr Arg Leu Ala Gln Glu Ala Ala Ile Ser Leu 310 315 Ser Asn Asn Thr Glu Glu Val Pro Lys Ile Lys Pro Cys Lys Asp His 325 330 Phe Trp Phe His Lys Pro Glu Leu Val Leu His Leu Ile His Phe Ile 340 345 Leu Phe Gln Asn Ser Phe Glu Ile Ser Phe Phe Phe Trp Ile Leu Val 360 Ser Glu Gly Phe Gly Ser Cys Met Met Glu Arg Lys Pro Tyr Val Ile Ser Arg Leu Val Ile Gly Val Ile Ile Glu Val Ile Cys Ser Tyr Ile 390 395 Thr Leu Pro Leu Tyr Ala Ile Val Thr His Met Thr Gly Gln Ile Lys 410 Leu His Gly Phe Gly Ser Arg Val His Glu Ser Val His Gly Trp Ile Gly Leu Arg Lys Lys Pro Phe Ser Phe Trp Lys Ile Pro Gly Gly Asp - 440 Pro Asn Ala Asp Ser Gly Arg Glu Ala Asp Val Thr Arg Arg Val Ala 455 Lys Glu Arg Ser Gly Ser Ser Arg Ser Met Pro Met Ala Pro Ala Asp 465 470 Glu Ile Val Thr Val Asp Asp Val Ala Val Ala Ala Ala Val Gly 485 490

Gln Gly Pro

<210> 13 <211> 1798 <212> DNA <213> Zea mays

<220> <223> Mlo8

```
<400> 13
ccgggagcgg caagactggg acacgccagc cctttatttc gagctttctg cgtqcqqqaq 60
gggggttgac aggcgatggc ggccgagggc gaggcggcgg cgctggagtt cacaccgacg 120
tggatcgtcg cggcggtctg ctctctcatc gtgctcctct cgctcgtcgc cgagcgatgc 180
ctccactacc teggcaagac getcaagagg aagaaccaga ageegetett egaggegetg 240
ctcaaggtca aagaagagtt gatgcttctg gggttcatct ccctgctgct gacggtgttc 300
caggggatga tccggaggac gtgcatccct gaacgctgga cattccacat gctgccatgc 360
gagaagccag atgagaaggc cggtgaggcc gccaccatgg agcattttgt agggacgctt 420
ggcaggatcg gtaggcgtct gttgcaggaa ggcactgctg gggctgagca atgccagaag 480
aagggaaaag ttccactttt gtcccttgaa gccatacatc agctgcacat tttcatattt 540
gttctggcaa tcacacatgt tattttcagc gtcacaacta tgcttttagg aggtgcacag 600
atacaccaat ggaaacagtg ggagaatgga attaaaaaag atgctcctgg aaatgggcct 660
aaggtaacca atgtacatca tcatgaattt atcaagaaac gttttaaggg tattggcaaa 720
gattctataa tattgagttg gctgcattct tttggtaagc agttttatag atcagtatct 780
aaatcagatt acaccacaat gcgtcttggt tttatcatga ctcactgccc tggaaatcca 840
aaatttgatt tocatagata catggtaagg gttttagagg cggattttaa gaaagtggta 900
ggcataagct ggtacttgtg ggtcttcgtg gtgatatttc tgttgctgaa tgttaatggc 960
tggcacacat actittggat tgctttcctt ccccttattc ttctgttagc cattggcact 1020
aagctggagc atgtcatagc tcagctagcc catgatgtag ctgagaagca cacagcggtc 1080
gagggcgatg tgatcgtaaa accatcagat gaacacttct ggttcggcaa gcctagggtt 1140
atcctttacc tgatccactt catcctcttt cagaatgcgt ttgagattgc gtttttcttc 1200
tggatactga gcacttatgg attcgactcg tgcatcatgg gacaagttcg ttttattgtg 1260
ccaaggettg teateggggt ggttatteag ettetetgea getacageae ettgeetetg 1320
tatgcaattg taacccagat ggggagctgc tacaagaagg agatcttcaa cgagcatgtg 1380
cagcagggcg tcctgggctg ggctcagaag gtcaagatga aaaagggact gaagggagct 1440
gcatctgcta gcaaggacga atcgattacc aatgccgatt cggcaggacc ttccgttaag 1500
attgaaatgg cgaaggctgg ggaggatgtt gagatcgttg gaaacacagg ttgattggga 1560
caatagggtg cccgtgttgt aatgatgtaa caggttaata tgccatcatc tttttttgta 1620
gatactagat agcttgctgt ggcaataccg caatagcggt gaactagaga aggtgagttt 1680
gggcccggga gcctcatctg ttatcggtcc agtaggaagc aaattcttat atacgggata 1740
tcgataagaa atgaactaag aacatgttcc tggattcatt aaaaaaaaa aaaaaaaa
<210> 14
<211> 492
<212> PRT
<213> Zea mays
<220>
<223> Mlo8
<400> 14
Met Ala Ala Glu Gly Glu Ala Ala Leu Glu Phe Thr Pro Thr Trp
                                     10
Ile Val Ala Ala Val Cys Ser Leu Ile Val Leu Leu Ser Leu Val Ala
```

25

| Glu | Arg | Cys 35 | Leu | His | Tyr | Leu | Gly 40 | Lys | Thr | Leu | Lys | Arg 45 | Lys | Asn | Gln |
|------------|------------|------------|------------|------------|------------|------------|-------------|------------|-------------|------------|------------|------------|------------|------------|------------|
| Lys | Pro 50 | Leu | Phe | Glu | Ala | Leu 55 | Leu | Lys | Val | Lys | Glu 60 | Glu | Leu | Met | Leu |
| Leu 65 | Gly | Phe | Ile | Ser | Leu 70 | Leu | Leu | Thr | Val | Phe 75 | Gln | Gly | Met | Ile | Arg 80 |
| Arg | Thr | Cys | Ile | Pró 85 | Glu | Arg | Trp | Thr | Phe 90 | His | Met | Leu | Pro | Cys 95 | Glu. |
| Lys | Pro | Asp | Glu 100 | Lys | Ala | Gly | Glu | Ala 105 | Ala | Thr | Met | Glu | His 110 | Phe | Val |
| Gly | Thir | Leu 115 | Gly | Arg | Ile | Gly | Arg 120 | Arg | Leu | Leu | Gln | Glu 125 | Gly | Thr | Ala |
| Gly | Ala 130 | Glu | Gln | Cys | Gln | Lys 135 | Lys | Gly | Lys | Val | Pro 140 | Leu | Leu | Ser | Leu |
| Glu 145 | Ala | Ile | His | Gln | Leu 150 | His | Ile | Phe | Ile | Phe 155 | Val | Leu | Ala | Ile | Thr 160 |
| His | Val | Ile | Phe | Ser 165 | Val | Thr | Thr | Met | Leu 170 | Leu | Gly | Gly | Ala | Gln 175 | Ile |
| His | Gln | Trp | Lys 180 | Gln | Trp | Glu | Asn | Gly 185 | Ile | Lys | Lys | Asp | Ala 190 | Pro | Gly |
| Asņ | Gly | Pro 195 | Lys | Val | Thr | Asn | .Val 200 | His | His | His | Glu | Phe 205 | Ile | Lys | Lys |
| Arg | Phe 210 | Lys | Gly | Ile | Gly | Lys 215 | Asp | Ser | Ile | Ile | Leu 220 | Ser | Trp | Leu | His |
| Ser 225 | Phe | Gly | Lys | Gln | Phe 230 | Tyr | Arg | Ser | Val | Ser 235 | Lys | Ser | Asp | Tyr | Thr 240 |
| Thr | Met | Arg | Leu | Gly 245 | Phe | Ile | Met | Thr | .His 250 | Cys | Pro | Gly | Asn | Pro 255 | Lys |
| | - | | 260 | | | | | 265 | | | | | 270 | Phe | - |
| Lys | Val | Val 275 | Gly | Ile | Ser | Trp | Tyr 280 | | Trp | Val | Phe | Val 285 | Val | Ile | Phe |

Leu Leu Asn Val Asn Gly Trp His Thr Tyr Phe Trp Ile Ala Phe
290 295 300

Leu Pro Leu Ile Leu Leu Leu Ala Ile Gly Thr Lys Leu Glu His Val 305 310 315 320

Ile Ala Gln Leu Ala His Asp Val Ala Glu Lys His Thr Ala Val Glu 325 330 335

Gly Asp Val Ile Val Lys Pro Ser Asp Glu His Phe Trp Phe Gly Lys 340 345 350

Pro Arg Val Ile Leu Tyr Leu Ile His Phe Ile Leu Phe Gln Asn Ala 355 360 365

Phe Glu Ile Ala Phe Phe Phe Trp Ile Leu Ser Thr Tyr Gly Phe Asp 370 375 380

Ser Cys Ile Met Gly Gln Val Arg Phe Ile Val Pro Arg Leu Val Ile 385 390 395 400

Gly Val Val Ile Gln Leu Leu Cys Ser Tyr Ser Thr Leu Pro Leu Tyr 405 410 415

Ala Ile Val Thr Gln Met Gly Ser Cys Tyr Lys Lys Glu Ile Phe Asn 420 425 430

Glu His Val Gln Gln Gly Val Leu Gly Trp Ala Gln Lys Val Lys Met
435
440
445

Lys Lys Gly Leu Lys Gly Ala Ala Ser Ala Ser Lys Asp Glu Ser Ile 450 455 460

Thr Asn Ala Asp Ser Ala Gly Pro Ser Val Lys Ile Glu Met Ala Lys 465 470 475 480

Ala Gly Glu Asp Val Glu Ile Val Gly Asn Thr Gly
485 490

<210> 15

<211> 1557

<212> DNA

<213> Zea mays

<220>

<223> Mlo9

```
<400> 15
cattcaccga ggagaaatct gaaaactagt taccataacc atgaaggctg ccgtgaggga 60
tatgagtcat ttgtttcgca tgaaggtttg gagcagctgc accggtttat atttgtaatg 120
gctgtgactc atgtgactta tagctgcctg acgatgttac tagcaatact caagatccat 180
aaatggagaa aatgggagga tgaagcattc agggataatc atgaatcatt ttctcagatc 240
gcatatgagt cagcaactag aaggcaacca gcacttacca aatcctattc attccgctct 300
tggagccaaa ataatgtggt catgtggctt gtttgcttta ttgcgcaatt tggtcagtct 360
gttgttcgag cagactatct tatcctccgc aagggtttta taatgaccca caatcttccg 420
ccaacatatg atttccacaa ttacatgata cgctcaatgg aagaggagtt tgagaagatt 480
gtcggagtga gtggactgtt gtggggcttc gttgttgctt ttatgttatt taatgtagac 540
ggatccaacc tgtacttttg gatagcaatt cttcctgtaa ctcttgttct tctggtgggt 600
gcaaagctgc agcatgtgat tgcgactcta acagcagagg gcgcaaagat gagcacctac 660
gggccaagga tacagccaag ggatgatctc ttttggttca agaaaccaga gtttctcctt 720
tggttgatac acttcgttct ctttcagaat gccttcgagt tggcttcgtt cttctggttc 780
tggtggcaat ttggttatga ttcatgcttc atcaaaaacc accttttggt atattgccgc 840
cttatactgg ggtttgctgg acagttcctg tgcagttaca gtacattacc tgtatatgcg 900
ctggtcactc agatggggtc caagtacaag gctgcgctga tcccgcggag gatcagggag 960
accatacatg ggtggggaaa agcgacgagg aagaagcgcc ggcgccgccg cggcgacgac 1020
tegacggtee geaeggagae gageaeggtg tgetegetea eggacgaega egaagaette 1080
gaagacgacg acgaccacca ccaccacgga ccgtcgtacg ataccccgag agccgggggc 1140
cgcccgccgt acctgaagat cgagacgcat cgtcagtcgg gcagcgggca cgacggccc 1200
aggcccggcg gcaccccgtg cttccacccc ageggcagcg gcagegggca cgccatgctc 1260
ctgcggcagg cctccgtctc cgcgccgtcg tcgccgtcgt accgcggagg caataacgtg 1320
acaaggtcgg cgtccatgcc cgggatcgcc gcgctgagga caacgggctc cggcacgccg 1380
acgcgcgtga gccatgagga gcctacttga tgcgcgcccg tgcatgccat ggatggcttg 1440
ctagtgcaga cgtactgagg actgagctgc tagtgtagca ccggatttga aggtatatcg 1500
atatatata acacacgaaa agatttgggg tgacaaaaaa aaaaaaaaa aaaaaaa
<210> 16
<211> 469
<212> PRT
<213> Zea mays
<220>
<223> Mlo9
<400> 16
His Ser Pro Arg Arg Asn Leu Lys Thr Ser Tyr His Asn His Glu Gly
Cys Arg Glu Gly Tyr Glu Ser Phe Val Ser His Glu Gly Leu Glu Gln
Leu His Arg Phe Ile Phe Val Met Ala Val Thr His Val Thr Tyr Ser
       . 35
Cys Leu Thr Met Leu Leu Ala Ile Leu Lys Ile His Lys Trp Arg Lys
```

55

50

| Trp 65 | Glu | Asp | Glu | Ala | Phe 70 | Arg | Asp | Asn | His | Glu 75 | Ser | Phe | Ser | Gln | Ile 80 |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Ala | Tyr | Glu | Ser | Ala 85 | Thr | Arg | Arg | Gln | Pro 90 | Ala | Leu | Thr | Lys | Ser 95 | Tyr |
| Ser | Phe | Ârg | Ser 100 | Trp | Ser | Gln | Asn | Asn 105 | Val | Val | Met | Trp | Leu 110 | Val | Cys |
| Phe | Ile | Ala 115 | Gln | Phe | Gly | Gln | Ser 120 | Val | Val | Aṛg | Ala | Asp 125 | Tyr | Leu | Ile |
| Leu | Arg 130 | Lys | Gly | Phe | Ile | Met 135 | Thr | His | Asn | Leu | Pro 140 | Pro | Thr | Tyr | Asp |
| Phe 145 | His | Asn | Tyr | Met | 11e 150 | Arg | Ser | Met | Glu | Glu 155 | Glu | Phe | Glu | Lys | Ile 160 |
| Val | Gly | Val | Ser | Gly 165 | Leu | Leu | Trp | Gly | Phe 170 | Val | Val | Ala | Phe | Met 175 | Leu |
| Phe | Asn | Val | Asp 180 | Gly | Ser | Asn | Leu | Tyr 185 | Phe | Trp | Ile | Ala | Ile 190 | Leu ' | Pro |
| Val | Thr | Leu 195 | Val | Leu | Leu | Val | Gly 200 | Ala | Lys | Leu | Gln | His 205 | Val | Ile | Ala |
| Thr | Leu 210 | Thr | Ala | Glu | Gly | Ala 215 | Lys | Met | Ser | Thr | Tyr 220 | Gly | Pro | Arg | Ile |
| Gln 225 | Pro | Arg | Asp | Asp | Leu 230 | Phe | Trp | Phe | Lys | Lys 235 | Pro | Glu | Phe | Leu | Leu 240 |
| Trp | Leu | Ile | His | Phe 245 | Val | Leu | Phe | Gln | Asn 250 | Ala | Phe | Glu | Leu | Ala 255 | Ser |
| Phe | Phe | Trp | Phe 260 | Trp | Trp | Gln | Phe | Gly 265 | Tyr | Asp | Ser | Cys | Phe 270 | Ile | Lys |
| Asn | His | Leu 275 | Leu | Val | Tyr | Cys | Arg 280 | Leu | Ile | Leu | Gly | Phe 285 | Ala | Gly | Gln |
| Phe | Leu 290 | Cys | Ser | Tyr | Ser | Thr 295 | Leu | Pro | Val | Tyr | Ala 300 | Leu | Val | Thr | Gln |
| Met 305 | _ | Ser | Lys | Tyr | Lys 310 | Ala | Ala | Leu | Ile | Pro 315 | Arg | Arg | Ile | Arg | Glu 320 |

Thr Ile His Gly Trp Gly Lys Ala Thr Arg Lys Lys Arg Arg Arg 325 330 335

Arg Gly Asp Asp Ser Thr Val Arg Thr Glu Thr Ser Thr Val Cys Ser 340 345 350

Leu Thr Asp Asp Asp Glu Asp Phe Glu Asp Asp Asp Asp His His His 355 360 365

His Gly Pro Ser Tyr Asp Thr Pro Arg Ala Gly Gly Arg Pro Pro Tyr 370 375 380

Leu Lys Ile Glu Thr His Arg Gln Ser Gly Ser Gly His Asp Gly Pro 385 390 395 400

Arg Pro Gly Gly Thr Pro Cys Phe His Pro Ser Gly Ser Gly 405 410 415

His Ala Met Leu Leu Arg Gln Ala Ser Val Ser Ala Pro Ser Ser Pro 420 425 430

Ser Tyr Arg Gly Gly Asn Asn Val Thr Arg Ser Ala Ser Met Pro Gly
435 440 445

Ile Ala Ala Leu Arg Thr Thr Gly Ser Gly Thr Pro Thr Arg Val Ser 450 455 460

His Glu Glu Pro Thr 465

<210> 17

<211> 533

<212> PRT

<213> Hordeum vulgare

<400> 17

Met Ser Asp Lys Lys Gly Val Pro Ala Arg Glu Leu Pro Glu Thr Pro 1 5 10 15

Ser Trp Ala Val Ala Val Phe Ala Ala Met Val Leu Val Ser Val
20 25 30

Leu Met Glu His Gly Leu His Lys Leu Gly His Trp Phe Gln His Arg
35 40 45

His Lys Lys Ala Leu Trp Glu Ala Leu Glu Lys Met Lys Ala Glu Leu

| | 50 | | | | | 55 | , | • | • | | 60 | ı | | | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Met 65 | | Val | Gly | Phe | Ile 70 | | Leu | Leu | Leu | Ile 75 | | Thr | Gln | Asp | Pro 80 |
| Ile | Ile | Ala | Lys | Ile 85 | | Ile | Ser | Glu | Asp 90 | | Ala | Asp | Val | Met 95 | |
| Pro | Cys | Lys | Arg 100 | Gly | Thr | Glu | Gly | Arg 105 | | Pro | Ser | Lys | Туг 110 | | Asp |
| Tyr | Cys | Pro | Glu | Gly | Lys | Val | Ala 120 | Leu | Met | Ser | Thr | Gly 125 | | Leu | His |
| Ģln | Leu 130 | His | Val | Phe | Ile | Phe 135 | Val | Leu | Ala | Val | Phe | His | Val | Thr | Tyr |
| Ser 145 | Val | Ile | Thr | Ile | Ala 150 | | Ser | Arg | Leu | Lys 155 | Met | Arg | Thr | Trp | Lys 160 |
| Lys | Trp | Glu | Thr | Glu 165 | Thr | Thr | Ser | Leu | Glu 170 | Tyr | Gln | Phe | Ala | Asn 175 | Asp |
| Pro | Ala | Arg | Phe 180 | Arg | Phe | Thr | His | Gln 185 | Thr | Ser | Phe | Val | Lys 190 | Arg | His |
| Leu | Gly | Leu 195 | Ser | Ser | Thr | Pro | Gly 200 | Ile | Arg | Trp | Val | Val 205 | Ala | Phe | Phe |
| Arg | Gln 210 | Phe | Phe | Arg | Ser | Val 215 | Thr | Lys | Val | Asp | Tyr 220 | Leu | Thr | Leu | Arg |
| Ala 225 | Gly | Phe | Ile | Asn | Ala 230 | His | Leu | Ser | Gln | Asn 235 | Ser | Lys | Phe | Asp | Phe 240 |
| His | Lys | Tyr | Ile | Lys 245 | Arg | Ser | Met | Glu | Asp 250 | Asp | Phe | Lys | Val | Val 255 | Val |
| Gly | Ile | Ser | Leu 260 | Pro | Leu | Trp | Gly | Val 265 | Ala | Ile | Leu | Thr | Leu 270 | Phe | Leu |
| Asp | Ile | Asn 275 | Gly | Val | Gly | Thr | Leu 280 | Ile | Trp | Ile | Ser | Phe 285 | Ile | Pro | Leu |
| Val | Ile 290 | Leu | Leu | Cys | Val | Gly 295 | Thr | Lys | Leu | Glu | Met 300 | Ile | Ile | Met | Glu |
| Met | Ala | Leu | Glu | Ile | Gln | Asp | Arg | Ala | Ser | Vạl | Ile | Lys | Gly | Ala | Pro |

305 310 315 320 Val Val Glu Pro Ser Asn Lys Phe Phe Trp Phe His Arg Pro Asp Trp 325 Val Leu Phe Phe Ile His Leu Thr Leu Phe Gln Asn Ala Phe Gln Met 345 Ala His Phe Val Trp Thr Val Ala Thr Pro Gly Leu Lys Lys Cys Tyr 360 His Thr Gln Ile Gly Leu Ser Ile Met Lys Val Val Gly Leu Ala 375 380 Leu Gln Phe Leu Cys Ser Tyr Met Thr Phe Pro Leu Tyr Ala Leu Val 385 390 -395 Thr Gln Met Gly Ser Asn Met Lys Arg Ser Ile Phe Asp Glu Gln Thr 405 410 Ser Lys Ala Leu Thr Asn Trp Arg Asn Thr Ala Lys Glu Lys Lys 425 Val Arg Asp Thr Asp Met Leu Met Ala Gln Met Ile Gly Asp Ala Thr 440 445 Pro Ser Arg Gly Ser Ser Pro Met Pro Ser Arg Gly Ser Ser Pro Val His Leu Leu His Lys Gly Met Gly Arg Ser Asp Asp Pro Gln Ser Ala-Pro Thr Ser Pro Arg Thr Gln Gln Glu Ala Arg Asp Met Tyr Pro Val 485 Val Val Ala His Pro Val His Arg Leu Asn Pro Asn Asp Arg Arg 505 Ser Ala Ser Ser Ser Ala Leu Glu Ala Asp Ile Pro Ser Ala Asp Phe 515 520 Ser Phe Ser Gln Gly 530

<210> 18 <211> 30 <212> DNA

| <213> | Artificial Sequence | |
|----------------|--|----|
| <220> | • | |
| <223> | Description of Artificial Sequence: | |
| | oligonucleotide primer | |
| | | |
| <400> | | |
| agttat | ccaa ggcatgccgg tggtaaaact | 30 |
| <210> | 19 | |
| <211> | | |
| <212> | • | |
| | Artificial Sequence | |
| | | |
| <220> | | |
| <223> | Description of Artificial Sequence:oligonucleotide | |
| | primer | • |
| | | |
| <400> | 19 | |
| aagtca | toga gggaggcato acttacag | 28 |
| .0.0. | | |
| <210> <211> | | |
| <211> | · | |
| | Artificial Sequence | |
| | | |
| <220> | | |
| <223> | Description of Artificial Sequence: | |
| • | oligonucleotide primer | |
| | | |
| <400> | 20 | |
| agagaa | gcca acgccawcgc ctcyatttcg tc | 32 |
| | | |

INTERNATIONAL SEARCH REPORT

int: onal Application No PCT/US 99/15255

| A. CLASSII IPC 7 | FICATION OF SUBJECT MATTER C07K14/415 C12N15/82 A01H5/00 | | |
|---|---|--|---|
| | o International Patent Classification (IPC) or to both national classifica | ation and IPC | |
| | SEARCHED | | |
| Minimum do IPC 7 | cumentation searched (classification system followed by classification CO7K C12N A01H | on symbols) | |
| | lion searched other than minimum documentation to the extent that si | | arched |
| Electronic d | ata base consulted during the international search (name of data bas | se and, where practical, search terms used) | |
| | | · | |
| C. DOCUM | ENTS CONSIDERED TO BE RELEVANT | | |
| Category * | Citation of document, with indication, where appropriate, of the rela | evant passages | Relevant to claim No. |
| x | WO 98 04586 A (INNES JOHN CENTRE ;PANSTRUGA RALPH (GB); BUESCHGES 5 February 1998 (1998-02-05) the whole document | | 1-11, 13-17 |
| X | DATABASE EMEST2 'Online! EMBL AC/ID AA660856, 14 November 1997 (1997-11-14) COVITZ P A ET AL.: "Expressed sectags from a root hair-enriched Metrunculata cDNA library" XP002119426 abstract | uence dicago | 13 |
| | | | |
| X Furt | ther documents are listed in the continuation of box C. | X Patent family members are listed in | n annex. |
| "A" docum consk "E" earlier filling o "L" docum which citatio "O" docum other "P" docum tater t | antegories of cited documents: ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) lent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed. | "T" later document published after the inter- or priority date and not in conflict with in- cited to understand the principle or the invention "X" document of particular relevance: the ci- cannot be considered novel or cannot involve an inventive step when the doc "Y" document of particular relevance: the ci- cannot be considered to involve an inv- document is combined with one or mo- ments, such combination being obvious in the art. "&" document member of the same patent f | the application but only underlying the almed invention be considered to summent is taken alone aimed invention entive step when the re other such docusto a person skilled |
| 1 | 9 October 1999 | 03/11/1999 | |
| Name and | mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016 | Authorized officer Oderwald, H | |

1